Exploring and Exploiting DNA Repair Mechanisms to Improve Suicide Gene Therapy with Ganciclovir. by Ladd, Brendon Paul
 
 
 
 
 
 
 
 
 
Exploring and Exploiting DNA Repair Mechanisms to Improve Suicide Gene Therapy 
with Ganciclovir 
 
by 
 
Brendon Paul Ladd 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Pharmacology) 
in The University of Michigan 
2012 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
Professor Donna S. Shewach, Chair 
Professor William D. Ensminger 
Professor Wendell W. Weber 
Associate Professor Thomas E. Wilson 
Assistant Professor Christine E. Canman 
 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my wife Lyndsey 
 
For all of her love and support 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
Acknowledgements 
 
I would like to thank Donna Shewach for five years of outstanding mentorship.  
Her guidance and patience got me to where I am today.  I am extremely grateful for 
time she spent helping me finishing my last experiments and the writing of this 
dissertation.  I would also like to thank the rest of the former and current lab members 
(Jess, Sheryl, Mike, Paul).  Especially Sheryl, who taught me valuable lab techniques, 
helped with writing, analyzing data and helping me develop early ideas into actual 
hypotheses.  I would also like to thank the members of my committee for providing 
valuable advice on my project.  In particular I would like to thank Dr. Wilson for his 
collaboration and letting me perform experiments in his lab and Dr. Canman for 
providing reagents and for all of her efforts as the chair of my qualifying exam.   
 I would also like to thank my parents, family, and friends for all of their support.  
Finally, I would like to thank my wife Lyndsey for moving with me to Michigan and 
believing in me throughout graduate school and supporting me in my career and 
everything else!   
 
 
 
 
 
 
iv 
 
 
 
 
 
 
Table of Contents 
Dedication                                                                                                                                   ii 
Acknowledgements               iii 
List of Figures              vi 
List of Abbreviations             viii 
Abstract                                       xi 
Chapter 
 I. Introduction              1 
History of nucleoside analogs and introduction to  
suicide gene therapy           2 
Pharmacology of GCV            6 
GCV in Gene therapy: Targeting Tumors         8 
GCV in Gene therapy: Bystander Effect        11 
GCV in Gene Therapy: Enhancement of HSV-TK Activity      13 
GCV in Gene Therapy: Summary         14 
Mechanism Based Enhancement of GCV Cytotoxicity      16 
Current Mechanistic Understanding of GCV Mediated Cell  
Killing in HSV-TK Expressing Tumor Cells       18 
DNA Repair and HR           22 
Rationale for KDAC Inhibitors to Improve HSV-TK/GCV  
Gene Therapy           26 
Background of KDAC Enzymes         27 
Pharmacology of Vorinostat (SAHA)         29 
4-Phenylbutyrate (4-BP) and Valproic Acid (VPA) as  
KDAC Inhibitors          30 
KDAC Inhibitors and Gene Therapy         31 
KDAC Inhibitors and DNA Damage Repair        32 
Conclusions            36 
References            46 
v 
 
 
 
 
II. Unrepairable DNA Double Strand Breaks Initiate Cytotoxicity 
     with HSV-TK/Ganciclovir                                                                             69 
 
 Summary             69 
 Introduction             70 
 Materials and Methods                                 73 
 Results              77 
 Discussion              82 
 Acknowledgements                                    86  
 References                                     97 
 
III. Vorinostat Synergistically Enhances HSV-TK/Ganciclovir Gene  
      Therapy by Inhibiting Homologous Recombination                                       101 
 
Summary             101 
 Introduction             102 
 Materials and Methods           105 
 Results              109 
 Discussion             119 
 Acknowledgements                  123 
 References                                        154 
 
IV. Conclusion                                                                                                               158 
 References             165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
 
 
 
 
 
 
 
 
List of Figures 
 
1.1 Development of ACV Pt. 1.       40 
1.2 Development of ACV Pt. 2.       41 
1.3 HSV-TK substrates.          42 
1.4 Homologous recombination.       44 
1.5 Structure of SAHA         45 
2.1 GCV induces a dose-dependent increase in γ-H2AX.    88 
2.2 GCV induces a dose-dependent increase in γ-H2AX expression.   89 
2.3 Time course of g-H2AX foci formation in response to GCV.   90 
2.4 araT induces a dose-dependent increase in γ-H2AX.    91 
2.5 Time course of γ-H2AX foci formation in response to araT.   92 
2.6 Time course of Rad51 foci formation in response to GCV or araT.    93 
2.7 Rad51 foci number in Rad51 positive cells in response to GCV or araT.   94  
2.8 Time course of Chk1 phosphorylation in response to GCV or araT.    95 
2.9 Time course of ATM activation in response to GCV or araT.     96 
3.1 GCV cytotoxicity in HR proficent and deficient CHO cells.   124 
3.2 HSV-TK expression in HR proficent (AA8) and deficient (irs1SF) cells.  125 
3.3 Effects of GCV on endogenous dNTP pools in AA8tk and irs1SFtk cells.  126 
3.4 GCVTP levels in AA8tk and irs1SFtk cells.       127 
3.5 GCVMP incorporation into DNA in AA8tk and irs1SFtk cells.   128 
3.6 Growth inhibition in AA8tk and irs1SFtk cells in response to GCV.    129 
3.7 Cell cycle effects in AA8tk cells in response to GCV.      130 
3.8 Cell cycle effects in irs1SFtk cells in response to GCV.      131 
3.9 Cell cycle effects of XRCC3 depletion in U251tk cells in  
response to GCV.         132 
3.10 Cell cycle effects of XRCC3 depletion in U251tk cells  
in response to GCV.           133 
3.11 RPA foci formation after IR in cells pretreated with GCV.     134 
vii 
 
3.12 RPA foci formation after IR in cells pretreated with GCV.   135 
3.13 Sensitivity of HeLa-D-GFPtk cells to GCV.       136 
3.14 Schematic of HR repair of the D-GFP reporter construct.     137 
3.15 GCV inhibits HR repair.        138 
3.16 Sensitivity of U251tk cells to GCV or SAHA.       139 
3.17 Histone 3 lysine 9 acetylation (AceH3K9) in response to SAHA.  140 
3.18 Sensitivity of U251tk cells to GCV and SAHA.       141 
3.19 Isobologram analysis of GCV and SAHA in U251tk cells.   142 
3.20 HSV-TK expression in response to SAHA.     143 
3.21 Effects of SAHA on GCVTP levels.        144 
3.22 GCVMP incorporation into DNA.        145 
3.23 Effects of SAHA on endogenous dNTP pools.       146 
3.24 CtIP expression in response to SAHA.      147 
3.25 Rad51 expression in response to SAHA.      148 
3.26 SAHA inhibits GCV induced Rad51 foci formation.    149 
3.27 SAHA inhibits HR repair.        150 
3.28 Sensitivity of HeLa-D-GFP-TK cells to SAHA.     151 
3.29 Cell cycle effects of GCV and SAHA.      152 
3.30 Isobologram Analysis of GCV and SAHA in AA8TK or irs1SFTK cells.  153 
4.1 GCV potentially inhibits DNA replication restart during HR.     164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
 
 
 
 
List of Abbreviations 
 
4-PB – 4-Phenylbutyrate a KDAC inhibitor 
53BP1 – A protein involved in double strand break repair 
5-FC – 5-fluorocytosine 
5-FdUMP – 5-fluorodeoxyuridine monophosphate 
5-FU – 5-fluorouracil  
ACV – Acyclovir 
araA – 9-β-D-ribofuranosyladenine 
araT – 1-β-D-arabinofuranosylthymine 
ATM – A kinase involved in sensing DNA damage, particularly double strand breaks 
ATR – A kinase involved in sensing DNA damage 
BER – Base excision repair 
BLM – Blooms Helicase, a helicase involved in DNA resection during DNA repair 
BRCA1 – A protein involved in HR, particularly in facilitating rad51 activity 
CAR – Coxsackievirus and adenovirus receptor (used by adenoviruses to infect cells) 
CHK1 – Involved in checkpoint activation.  Chk1 is activated by ATR kinase after DNA   
damage 
ix 
 
CMV – Cytomegalovirus 
CtIP – C-terminus Interacting Protein, an exonuclease that resects DNA during HR 
dGTP – deoxyguanosine triphosphate 
DNA2 – An exonuclease that resects DNA during HR  
dNTP – The triphosphate form of any nucleotide 
DSB – Double stand break 
EXO1 – An exonuclease that resects DNA during HR 
GCV – Ganciclovir 
GCVMP – Ganciclovir monophosphate 
GCVTP – Ganciclovir triphosphate 
HR – Homologous Recombination 
HSV-TK – Herpes simplex virus thymidine kinase 
HU – Hydroxyurea 
IR – Ionizing radiation 
KDAC – Lysine deacetylase  
MDR4 – Multidrug resistance protein 
MDR5 – Multidrug resistance protein 
MRE11 – An endonuclease involved in sensing DNA damage, part of the MRN complex 
MRN – A protein complex containing MRE11, RAD50 and NBS1 
NBS1 – A protein involved in sensing DNA damage, part of the MRN complex 
x 
 
NHEJ – Non-homologous end joining 
PEPT1 – A protein transporter involved in the absorption of amino acids in the intestine 
PEPT2 – A protein transporter involved in the absorption of amino acids in the intestine 
Polβ – polymerase β (involved in base excision repair) 
Rad50 – A protein involved in sensing DNA damage, part of the MRN complex 
RAD51 – A protein that mediates strand invasion during homologous recombination 
RAD52 – A protein involved in HR, particularly in facilitating rad51 activity 
RPA – A protein that binds ssDNA often generated from stalled DNA replication or 
resection 
SAHA – Suberoylanilide hydroxamic acid, a KDAC inhibitor also known as vorinostat 
SCE – Sister Chromatid Exchange, a deleterious event occurring during failed HR 
SGS1 – The yeast ortholog to mammalian CtIP, an exonuclease used during HR 
ssDNA – single stranded DNA 
TTP – Thymidine triphosphate 
VPA – Valproic acid, a KDAC inhibitor 
yCD – Yeast cytosine deaminase (deaminates 5-FC to 5-FU) 
γH2AX – The phosphorylated histone variant H2AX (which is phosphorylated upon DNA 
damage) 
 
 
 
xi 
 
ABSTRACT 
Exploring and Exploiting DNA Repair Mechanisms to Improve Suicide Gene Therapy with 
Ganciclovir 
 
By  
Brendon Paul Ladd 
 
Chair: Donna S. Shewach 
 
Exploring the unique mechanisms of anticancer drugs can provide the 
opportunity to identify novel targets for future drug development.  Suicide gene therapy 
with the herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) is a 
selective approach for the treatment of cancer.  Only the cells containing HSV-TK can 
activate GCV to a toxic metabolite, thus sparing normal dividing tissues.  Upon activation 
by HSV-TK and further metabolism by host cell enzymes, GCV becomes incorporated 
into the DNA of dividing tumor cells resulting in cell death by a unique mechanism 
compared to other HSV-TK substrates.  However, the underlying mechanistic differences 
that confer high anticancer activity for GCV are still unknown.  The studies described in 
this dissertation identify differences in the magnitude of DNA damage and the DNA 
repair pathways activated by GCV and a less toxic HSV-TK substrate, 1-β-D-
arabinofuranosylthymine.  Furthermore, the DNA repair pathway of homologous 
recombination (HR) is identified as a critical repair mechanism to survive GCV exposure.   
xii 
 
These observations suggest that inhibition of HR will improve GCV mediated 
tumor cell kill.  While there are no inhibitors specific for HR, this dissertation 
demonstrates that the lysine deacetylase inhibitor Vorinostat (SAHA) inhibits HR in 
response to GCV resulting in synergistic tumor cell kill.  Importantly, this synergy occurs 
only in cells proficient in HR demonstrating that the mechanism of synergy between 
GCV and SAHA is specifically due to inhibition of HR after GCV induced DNA damage.  
Collectively, these studies reveal that tumor cells activate the DNA repair pathway of HR 
in response to GCV and identify SAHA as a novel, mechanism based drug to enhance 
HSV-TK/GCV gene therapy.   
 
 
  
 
 
Chapter I 
 
 
Introduction 
The indiscriminate nature of traditional cancer chemotherapy, which targets 
all dividing cells, has initiated a search for more selective approaches such as 
suicide gene therapy. With this strategy, only the cells containing the suicide gene 
are capable of activating a prodrug to a toxic metabolite, thus conferring selectivity 
for tumor cells while sparing normal dividing tissues.  One of the most commonly 
used suicide gene therapy strategies transfers the cDNA for herpes simplex virus 
thymidine kinase (HSV-TK) into tumor cells followed by treatment with the antiviral 
drug ganciclovir (GCV).  This approach has demonstrated exquisite tumor cell kill 
both in cell culture models and xenograft studies.  However, the efficacy of this 
strategy in clinical trials has been limited, primarily due to low gene transfer.  To 
improve this gene therapy strategy, several mechanistic studies have been 
conducted to determine the mechanism of GCV.  Although progress has been 
reported, the exact mechanism by which GCV mediates tumor cell death has 
remained elusive.  The results presented in this dissertation demonstrate that cells 
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require the DNA repair pathway homologous recombination (HR) to survive 
exposure to GCV, and if repair fails, cell death occurs.  Furthermore, the data reveal 
that pharmacological inhibition of HR can synergistically increase tumor cell killing 
with HSV-TK/GCV.   
History of nucleoside analogs and introduction to suicide gene therapy 
Nucleoside analogs are small molecules that are structurally related to the 
endogenous nucleosides.  Similar to endogenous nucleosides, many nucleoside 
analogs are phosphorylated to the triphosphate form which can compete with 
endogenous nucleotides for incorporation into DNA.  Although the exact 
mechanism by which nucleoside analogs exert their cytotoxic effects remains 
unclear, many nucleoside analogs can inhibit the growth of tumors and viruses.  For 
this reason, nucleoside analogs are a mainstay in the treatment of viral infections 
and cancer.   
The first approved systemic antiviral drug was the nucleoside analog 
vidarabine (Adenine Arabinoside, araA) (Fig. 1.1), the use of which was restricted to 
life threatening infections due to accompanying toxicities such as nausea, vomiting, 
and bone marrow suppression(1).  Before the discovery of araA, the purine analog 
2,6-diaminopurine (Fig. 1.1) was developed by Burroughs Wellcome company 
which was used for the treatment of chronic granulocytic leukemia in adults(2-4).  
Although it was known that 2,6-diaminopurine was also active against vaccinia 
virus, the toxicity of the drug limited its use to cancer chemotherapy(4).  Gertrude 
Elion at Burroughs Wellcome hypothesized that diaminopurine arabinoside, which 
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contains the sugar group from araA, together with its base 2,6-diaminopurine (Fig. 
1.1) would be a superior antiviral compared to araA because the modified sugar 
would confer the same mild selectivity as araA while the modified base would be a 
poor substrate for metabolism by adenosine deaminase thus increasing the half life 
of the drug(4).  They observed that diaminopurine arabinoside was less cytotoxic 
than araA and the major metabolite, guanine arabinoside, had antiviral activity as 
well(4).  Although diaminopurine arabinoside appeared to produce promising 
results, Elion et al were unsure if this was sufficient to warrant full scale production 
of diaminopurine(4).  At this time, Schaeffer et al at the University of Buffalo 
demonstrated that nucleoside analogs of adenosine that were comprised of acyclic 
carbohydrate moieties lacking the 2’ and 3’ carbons (Fig. 1.2) were recognized by 
adenosine deaminase(5).  This work led Elion and colleagues at Burroughs 
Wellcome to hypothesize that other enzymes may recognize these analogs as 
well(4).  Further, others demonstrated that the herpes virus genome contained a 
thymidine kinase(6) and that another emerging compound, thymine arabinoside  
(araT) (Fig. 1.3) had strong antiviral activity(7) without inhibiting DNA replication in 
normal cells(8) presumably due to selective activation by HSV-TK(9) and selective 
interaction with the viral polymerase(8).  Based on these observations, Elion and 
colleagues screened for acyclic nucleoside analogs lacking both the 2’ and 3’ 
carbons and possessing antiviral activity(4).  They identified 2 compounds, (1) 
acyclic adenosine (Fig. 1.2), which had antiviral activity but required high 
concentrations to inhibit viral replication relative to araA(4) and (2) acyclic-2,6-
3
diaminopurine riboside (Fig. 1.2)(4;10).  Upon further study of acyclic-2,6-
diaminopurine riboside metabolism, it was revealed that the base was metabolized 
into guanine to produce acycloguanosine (Acyclovir; ACV) (Fig. 1.2)(10) and that 
ACV was the active antiviral compound and 100 times more active than the parent 
compound(11).  Fyfe et al at Burroughs Wellcome identified HSV-TK as the viral 
enzyme that activates ACV(10;12) and  ACV became the first truly selective antiviral 
drug.  It remains the front line therapy for herpes simplex virus (HSV) infections 
today(13).   
The requirement for activation of ACV by a viral enzyme provided a 
mechanism for selectivity to HSV infected cells(14;15).  In addition, following 
activation by HSV-TK, ACV is a 3000-fold better substrate for viral polymerase 
compared to human polymerase, thus providing another mechanism of selectivity 
for inhibiting viral replication(14-17).  In light of the remarkable selectivity of ACV 
for inhibiting the herpes virus, similar compounds were synthesized and tested for 
inhibition of a broader range of viral species and for selectivity for virally infected 
cells only.  One of these compounds was ganciclovir (GCV) (Fig. 1.3).  In addition to 
inhibiting herpes simplex virus (18-22) GCV is 100-fold more effective at inhibiting 
cytomegalovirus (CMV)(22-26) than ACV due to its selective activation by the CMV 
kinase UL97(27;28).  While GCV is more selective for the viral DNA polymerase 
compared to the human DNA polymerase, the magnitude of this polymerase 
selectivity is less than that observed with ACV(29).  However, GCV is still considered 
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to have excellent selectivity for virally infected cells due to the requirement for 
activation by a virally delivered kinase(20).     
Compared to deoxyguanosine, ACV lacks the 2’ and 3’ carbons on the sugar 
ring and GCV lacks only the 2’ carbon (Fig 1.2, 1.3, respectively).  Similar to 
endogenous nucleosides, GCV and ACV require phosphorylation to the mono, di, 
and then triphosphate forms to be activated(20-22).  The active triphosphate form 
can then be used as a substrate for DNA synthesis(14).   
Several of the preliminary studies demonstrating selectivity of ACV and GCV 
for inhibiting HSV versus host cell replication did so by measuring cell growth in 
cells with or without HSV infection(14-17).  These studies demonstrated that GCV 
and ACV are selective due to their requirement for HSV-TK to perform the initial 
phosphorylation to activate these compounds(30) and that cells containing HSV-TK 
are capable of phosphorylating GCV to levels that can inhibit cellular DNA synthesis.  
Moolten et al hypothesized that this selective cytotoxicity could be exploited to 
target cancer cells specifically and demonstrated that GCV could arrest clonal 
expansion of HSV-TK expressing cells in HSV-TK chimeric mice(31-36).  Although this 
approach has evolved significantly over time, many consider these studies to mark 
the beginning of the pursuit of HSV-TK/GCV as a gene therapy strategy for the 
treatment of cancer.  Currently, tumor cells are selectively targeted to express HSV-
TK, thus acting as a “suicide gene”.  Therefore, only the tumor cells containing the 
“suicide gene” are capable of activating a prodrug to a toxic metabolite, thus 
conferring selectivity for tumor cells while sparing normally dividing tissues.  
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Importantly, this approach has demonstrated excellent tumor cell kill in animal 
models in which strong tumor growth inhibition and complete tumor regressions 
have been observed(37;38). 
 
Pharmacology of GCV 
At the cellular level, functional studies have suggested that GCV can be 
transported across the membrane by a purine nucleobase carrier and nucleoside 
transporter(39-42).  Efflux of phosphorylated metabolites of GCV occurs by the 
multidrug resistance protein 4 (MDR4) and MDR5(43-45).  For GCV to be cytotoxic, 
it must first be activated to its monophosphate form by a viral kinase(20-22) such as 
HSV-TK then further phosphorylated to the di and triphosphate forms by guanylate 
kinase and nucleoside diphosphokinase, respectively(22;23;46-48).  The 
triphosphate form of GCV (GCVTP) is considered the active metabolite (21) and 
competes with dGTP for incorporation into viral DNA which inhibits viral 
replication(20-22).     
ACV is exquisitely selective for inhibiting HSV 1 and 2 replication therefore 
ACV is primarily used for the treatment of HSV 1 and 2 infections(49).  Ganciclovir 
inhibits HSV 1 and 2 at concentrations similar to acyclovir (ACV)(18;50) despite the 
fact that GCV is a better substrate for HSV-TK (Km=66µM vs. 426µM, 
respectively)(22).  In addition to inhibiting HSV 1 and 2, GCV can inhibit HSV 
6(51;52), varicella zoster virus(18), Epstein-Barr virus(18;53), and cytomegalovirus 
(CMV) (27;28) at lower concentrations than ACV(25;48).  Clinically, the primary use 
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for GCV is in the front line treatment of life threatening CMV infections in immune 
compromised patients and for prevention of such infections in solid organ 
transplant recipients(54-56).  CMV does not contain a thymidine kinase, however 
the superior efficacy of GCV compared to ACV in inhibiting CMV is due to the fact 
that GCV can be activated by the CMV kinase UL97 (27;28).  While the 
concentration of ACV required to inhibit CMV replication are above clinically 
achievable plasma concentrations, the concentrations which GCV inhibits CMV are 
10 to 100 times lower (0.2-2.8ug/ml) than what is required with ACV(26).  
Therefore GCV is the superior antiviral for the treatment of CMV infections(13).  
The dose limiting toxicities associated with GCV treatment include neutropenia (15-
40%) and thrombocytopenia (5-20%)(13;54;57).  Other side effects include 
gastrointestinal disturbance (nausea, pain and diarrhea)(5-15%), headache and 
more rarely other CNS effects such as behavioral changes and convulsions(13;54).  
At therapeutic doses, the toxicities associated with ACV are relatively mild 
compared to GCV making ACV the frontline therapy for HSV 1 and 2 infections.  
However, ACV has little efficacy in patients with CMV infections.  GCV is an 
efficacious treatment for CMV infections and therefore is used as a frontline 
therapy despite the associated toxicities(13).   
Due to the poor oral absorption of GCV (6-9%)(13;54), the drug is 
administered as a 1 hour intravenous infusion of 2.5mg/kg every 8 hours or 5mg/kg 
every 12 hours for 14-21 days(54).  After an IV bolus, GCV achieves peak and trough 
plasma concentrations of 8-11ug/ml and 0.6-1.2ug/ml, respectively, with a half life 
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of 2-4hr in patients with normal renal function(13;54;58;59).  Additionally, 90% is 
excreted by glomerular filtration as unchanged drug(13;56).  To circumvent the 
requirement for IV injection of GCV, valganciclovir was developed.  Valganciclovir is 
similar in structure to ganciclovir with the exception that valganciclovir contains a 
valine conjugated to the carbohydrate moiety by an ester linkage.  The conjugated 
valine allows uptake by both PEPT1 and PEPT2 transporters in the intestine(60-62).  
Following absorption, valganciclovir is rapidly and completely hydrolyzed into GCV 
by liver and intestinal esterases.  The bioavailability of valganciclovir is 
approximately 61% with peak GCV plasma concentrations of approximately 
6.1µg/ml.  After an oral dose of GCV, the maximal concentration of GCV achieved in 
plasma is 59-67% of that achieved with intravenous GCV(63) and peak plasma 
concentrations of valganciclovir after an oral dose occur 1-2.5 hours post 
administration(55;62;64).  Importantly, valganciclovir was as equally as efficacious 
as intravenous GCV for the treatment of CMV retinitis in clinical trials(63).    
 
GCV in Gene therapy: Targeting Tumors 
The first step in HSV-TK/GCV gene therapy is delivery of the HSV-TK cDNA to 
the tumor cells.  This is often accomplished by direct intratumoral injection of an 
adenovirus containing the cDNA for HSV-TK(65).  Although many viral vectors have 
been used for gene therapy, adenoviral vectors are commonly used because they 
have demonstrated superior transduction and suicide gene expression relative to 
other viruses such as retroviruses(65).  Furthermore, retroviral vectors integrate  
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their genome into the host cell DNA which has resulted in adverse events such as 
leukemia in previous gene therapy clinical trials(66).  The adenoviral genome does 
not integrate into the DNA of the host cells, thus eliminating the potential safety 
issue associated with integrating viruses such as retroviruses.  Finally, adenoviruses 
infect cells by docking to the transmembrane Coxsackievirus and adenovirus 
receptor (CAR) which is ubiquitously expressed(67) and therefore can be used to 
infect virtually any tumor cells.      
Due to the difficulty of targeting all of the tumor cells within a tumor, the 
use of gene therapy in the treatment of cancer is limited by the inability to 
transduce enough tumor cells to completely eliminate a tumor.  In fact, it has been 
reported that fewer than 1% of cells within a tumor are successfully transduced via 
gene therapy protocols in humans(68).  Therefore, suicide gene therapy depends 
heavily on improved methods to transduce more tumor cells.   To circumvent the 
problem of low tumor cell transduction with intratumoral injection approaches, 
viruses carrying genes under tumor specific promoters have been generated.  
Although systemic delivery of these viruses has the potential to transduce normal 
and tumor cells, it is considered selective for tumor cells because a tumor specific 
promoter will not result in transcription of the suicide gene in normal cells.  For 
example, DiMaio et al generated retroviral vectors carrying HSV-TK under the 
carcinoembryonic antigen (CEA) promoter to target pancreatic carcinoma(68;69).  
CEA is reactivated in pancreatic cancer cells, therefore only tumor cells will express 
proteins under the CEA promoter resulting in the expression of HSV-TK only in 
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tumor cells.  A limitation with this approach is the tumor specific promoters drive 
relatively weak expression of the gene of interest compared to that achieved with a 
viral promoter(68;70).  Therefore, this approach is limited by poor expression of the 
suicide gene(71). As a result, intratumoral injection with a stronger ubiquitously 
expressing promoter is still widely used.  One such promoter is that of 
cytomegalovirus (CMV).  The CMV promoter is highly effective at driving high 
expression of exogenously delivered genes and therefore commonly used to drive 
protein expression in gene therapy strategies(68;70;72).  In an effort to improve 
transduction and transgene expression, several studies have delivered suicide 
genes via adenoviruses, which have the ability to infect any cell using the strong 
CMV promoter to drive expression of the suicide gene. To minimize the expression 
of the suicide gene in normal host tissues the use of adenoviral vectors delivering 
CMV driven genes is best suited for direct intratumoral injection.   Thus this 
approach is most useful for tumors in which local progression is the major clinical 
problem(65;73-75).   
The use of replication competent (oncolytic) adenoviruses to further 
improve gene transduction has produced some success(73;74).  With this approach, 
adenoviral replication results in the eventual lysis of the host cell which then 
releases additional viral particles within the tumor which in turn can infect and kill 
surrounding tumor cells.  When administered alone, this approach has 
demonstrated some positive results(68).  However, this approach has not increased 
tumor cell transduction enough to be considered an efficacious treatment(68).  The 
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co-delivery of HSV-TK with cytokines known to produce tumor immunity, such as 
IL2 has also been attempted in an effort to circumvent transduction limitations(76).  
With this approach, more immune cells are recruited to the tumor thus creating an 
immune response against tumor cells, or “tumor immunity,” which results in 
greater tumor cell death despite low tumor cell transduction(68).  While such 
suicide gene/cytokine combinations have demonstrated some promising results 
both in animal models and human studies, the level of success has not been 
sufficient to advance these approaches beyond clinical trials(68).  
 
GCV in Gene therapy: Bystander Effect 
The required activation of GCV to a phosphorylated form results in charged 
molecules that cannot easily traverse the cell membrane.  Despite this, 
phosphorylated metabolites of GCV are transferred to neighboring non-HSV-TK 
containing cells by a process referred to as the “bystander effect”(32;77).  The 
primary mechanism by which  bystander cells receive GCV metabolites and 
subsequently die occurs primarily via gap junctional  intercellular  communication 
using a class of proteins called connexins(78-80).  Connexins are transmembrane 
proteins that form a hemichannel that aligns with a connexin hemichannel on an 
adjacent cell resulting in unique pore structure or gap junction that connects the 
cytoplasm of both cells(81).   The transfer of phosphorylated GCV to bystander cells 
facilitates the accumulation of active GCVTP metabolites and cell death in 
bystander cells despite the absence of HSV-TK in these cells.  As expected, several 
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reports demonstrate the extent of gap junctional communication correlates with 
bystander cell killing and that there is a lack of bystander cell killing in the absence 
of gap junctional communication(78;79;81-85).  In light of the fact that connexins 
mediate bystander cell killing, it was hypothesized that pharmacologic agents that 
increase or activate connexin expression would increase bystander cell killing in 
tumors either deficient or low in expression levels of connexins.  Indeed, this 
principal was demonstrated by Touraine et al using  the flavonoid-like compound 
apigenin and the cholesterol lowering drug lovastatin, in a mouse xenograft  
model(86).   
Several studies demonstrate bystander killing in cells that were thought to 
be deficient in gap junctional communication, such as SW620 colon carcinoma 
cells(87).  HeLa cells are also thought to be devoid of connexin proteins.  However, 
while Gentry et al demonstrated that there was no rapid transfer of fluorescent dye 
between HeLa cells suggesting these cells lacked gap junctional communication, a 
more sensitive flow cytometric technique revealed a detectable level of 
communication over a prolonged time period.  Furthermore, the authors 
demonstrated that phosphorylated GCV was transferred to bystander cells(88).  
Studies performed in mouse models demonstrated that combining HSV-TK/GCV 
gene therapy with pharmacological agents that enhance the cytotoxicity of GCV 
resulted in prolonged survival, strong tumor growth inhibition and some complete 
regressions when only a fraction of the tumor contained HSV-TK expressing 
cells(38;75;88).  It has recently been reported in a number of studies that lysine 
12
deacetylase inhibitors (KDACs) increase gap junctional communication by increasing 
the expression of connexin 43(89-91).  Due to the limited ability to transduce tumor 
cells with exogenous genes such as connexins, increasing the expression of 
endogenous connexin proteins with KDAC inhibitors such as Vorinostat (SAHA) may 
prove to be a superior method of increasing gap junctional communication.   
  
GCV in Gene Therapy: Enhancement of HSV-TK Activity 
The cytotoxicity of GCV is dependent on the amount of GCVTP within the 
cell, which is dependent on the initial activation by HSV-TK(92).  Previous studies 
have demonstrated the ability to alter thymidine metabolism of HSV-TK by random 
mutagenesis of the enzyme(93). This led Black et al to hypothesize that altering 
HSV-TK will yield an enzyme that preferentially metabolizes GCV.  To test this 
hypothesis, they used semi-random mutagenesis of the active site of HSV-TK to 
isolate mutant enzymes that enhance the cytotoxicity of GCV relative to WT HSV-TK 
as measured by growth inhibition in C6 glioma cells.  (94-97).  These studies yielded 
one HSV-TK mutant referred to as the SR39 variant.  SR39 contains five amino acid 
changes within the catalytic site of HSV-TK that together result in a decrease of the 
affinity of the enzyme for thymidine, a direct competitor to GCV for binding to the 
active site(97).  This decrease in competition between GCV and thymidine for SR39 
HSV-TK resulted in an 83 fold kinetic advantage for activating GCV.  In cell culture 
models, this increased kinetic advantage corresponded to an almost 300 fold 
increase in GCV sensitivity of rat C6 glioma cells expressing SR39 HSV-TK compared 
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to cells expressing WT HSV-TK.  Furthermore, mouse xenograft studies revealed 
growth inhibition in tumors expressing the SR39 HSV-TK variant at doses of GCV 
that did not inhibit tumor growth in tumors expressing WT HSV-TK(97).  The 
enhancement of GCV activation by mutant TK also resulted in an increase the 
number of activated GCV molecules to bystander cells, thus enhancing bystander 
killing(95).  Therefore, the generation of mutant HSV-TK enzymes that are capable 
of enhancing GCV activation compared to wild type is a valuable contribution to the 
improvement of the efficacy of HSV-TK/GCV gene therapy.   
 
GCV in Gene Therapy: Summary 
Each of the approaches to improve gene therapy discussed above has 
demonstrated promising results.  However, it appears that the most promising 
approach for improving gene therapy will be achieved by combining several 
approaches that improve tumor transduction in addition to pharmacological 
approaches that exploit the biology of tumor cells and the mechanism of GCV 
mediated cytotoxicity.  For example, Freytag et al demonstrated excellent tumor 
cell kill in preclinical studies combining ionizing radiation (IR) with use of a 
replication competent adenovirus to deliver a fusion protein containing two suicide 
enzymes, followed by the administration of two prodrugs.  The suicide enzyme 
fusion protein is the SR-39 HSV-TK variant fused to the yeast cytosine deaminase 
(yCD) enzyme, which metabolizes 5-fluorocytosine to the chemotherapeutic agent 
5-fluorouracil(73;74).  This double suicide gene therapy and IR combination 
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resulted in a doubling of tumor growth delay compared to IR alone in mouse 
xenograft models.  Furthermore, when the double suicide enzyme was delivered by 
intratumoral injection with a replication competent adenovirus followed by IR, a 
25% cure rate in DU145 xenografts and a 44% cure rate in LnCaP xenografts was 
noted compared to a 0% cure rate with either cell line with IR alone.  Importantly, 
these  studies noted that there was no additional toxicity in the combination 
therapy groups versus the IR alone group(98;99).   
Based on the above results, clinical trials evaluating the combination of IR 
and gene therapy using a replication competent adenovirus to deliver yCD/HSV-
TK(SR-39), followed by GCV and 5-FC treatment, were initiated in men with 
prostate cancer who had previously failed standard therapy.  This combined 
approach produced an increase in the average prostate specific antigen doubling 
time from 17 to 31 months at the five year follow-up, which subsequently delayed 
the projected androgen suppression therapy by an average of two years(100).    
Importantly, 94% of all treatment related adverse events were considered mild to 
moderate in this trial whereas toxicities associated with most traditional 
chemotherapeutic regimens are generally severe(13).  Therefore, the delay in 
tumor growth combined with the lack of severe toxicity observed during this clinical 
trial demonstrates the potential of gene therapy as a selective cancer 
treatment(73).   
The successful approach described above combined several methods that 
had previously demonstrated promising results:  (1) use of a replication competent 
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adenovirus to increase the transduction efficiency of tumor cells and to increase 
the duration of detectable expression of the virally delivered proteins(101;102),  (2) 
use of  the SR-39 variant of HSV-TK to increase GCV phosphorylation and 
incorporation into DNA(97),  (3)  synergistic cytotoxicity with GCV and 5-FU (103-
105) ,  (4) at least additive cytotoxicity with replication competent adenoviruses 
and IR(106;107), and (5) synergistic cytotoxicity with 5-FU and, potentially, GCV 
when combined with IR(106-109).  Collectively, these studies demonstrate that 
combining several approaches to enhance gene therapy results in clinically 
beneficial treatments.  Combining this gene therapy approach with pharmacological 
enhancement of gap junctional communication and pharmacological enhancement 
of GCV cytotoxicity in tumor cells could provide additional efficacy of gene therapy 
approaches for the treatment of cancer.     
 
Mechanism Based Enhancement of GCV Cytotoxicity 
GCV is structurally similar to the endogenous nucleoside deoxyguanosine.  
GCV triphosphate (GCVTP) competes with dGTP for incorporation into DNA, an 
event that is required for GCV mediated cytotoxicity(92).  Previously, Boucher et al 
hypothesized that decreasing intracellular dGTP levels would decrease the 
competition for GCVTP and result in increased GCVMP incorporation into DNA and 
synergistically enhance GCV mediated cytotoxicity.  In support of their hypothesis, 
they demonstrated that decreasing dGTP with the antimetabolites hydroxyurea 
(HU)(38;75), gemcitabine (difluorodeoxycytidine; dFdCyd)(110), or 5-fluorouracil (5-
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FU)(105) produced a synergistic increase in GCV mediated cytotoxicity.  However, 
the mechanism by which these antimetabolites decreased dGTP differed.  HU and 
dFdCyd caused a decrease in dNTP pools by direct inhibition of ribonucleotide 
reductase (RR)(111;112), an enzyme responsible for the conversion of 
ribonucleoside diphosphates to deoxyribonucleoside diphosphates for subsequent 
incorporation into DNA.  While dFdCyd is useful clinically, decreases dNTPs, and 
results in strong synergistic cell kill when combined with GCV, dFdCyd can also be 
incorporated into DNA(112).  The multiple mechanisms of dFdCyd mediated cell kill 
makes it difficult to evaluate the mechanism underlying its contribution to the 
synergistic increase in cell kill observed when combined with GCV.  Conversely, HU 
affects primarily dNTPs thereby making it a valuable research tool for evaluating 
the role of deoxynucleotide pool imbalances in eliciting an increase in GCV 
mediated cell death. 
HSV-TK/GCV gene therapy is synergistically enhanced when combined with 
yCD/5-FC gene therapy (73;74;113), however the contribution of dNTP pool 
imbalance as a result of 5-FC treatment was not initially appreciated.  yCD converts 
5-FC to 5-FU providing a selective method for delivering 5-FU to tumors while 
simultaneously avoiding normal tissue toxicity(114).  5-FU is metabolized by 
intracellular enzymes to 5-FdUMP which inhibits thymidylate synthase, an enzyme 
required to convert dUMP to dTMP, ultimately resulting in depleted thymidine 
triphosphate (dTTP) levels within the cell(115).  Through allosteric regulation of 
ribonucleotide reductase, the decrease in dTTP resulted in the intracellular 
17
depletion of dGTP.  In addition to altering dNTP pools, 5-FU can be metabolized to 
nucleotides which are incorporated into both DNA and RNA, thereby making it 
difficult to conclude whether 5-FU mediated changes in dNTP pools or 
incorporation of the drug is responsible for the enhancement of GCV mediated 
cytotoxicity(115).  To address this question, Boucher et al demonstrated that 
supplementation with deoxyguanosine during 5-FC incubation and prior to GCV 
incubation decreased the incorporation of GCVMP into DNA and subsequent 
cytotoxicity compared to concurrent 5-FC/GCV treatment(105).  These studies 
support the hypothesis that the increase in GCV cytotoxicity is the result of the 5-FC 
mediated decrease in dGTP and increased incorporation of GCVMP into DNA.  
Furthermore, these studies demonstrated that mechanistic approaches can 
enhance efficacy of gene therapy strategies, an observation that will be considered 
for improving future gene therapy clinical trials.   
 
Current Mechanistic Understanding of GCV Mediated Cell Killing in HSV-TK 
Expressing Tumor Cells 
While it is known that incorporation of GCVTP into DNA is required for 
cytotoxicity, the exact mechanism by which this event causes cell death remains 
largely unknown.   Studies in B16 murine melanoma cells documented a change in 
cellular morphology, due to the reorganization of components of the cytoskeletal 
components, and an accumulation of cells in G2/M of the cell cycle following 
exposure to GCV(116).    GCV also initiates apoptosis as evidenced by a decline in 
18
Bcl-2 levels and activation of caspases, following treatment(117).  While these 
studies provide details of the downstream consequences of GCV induced cell death, 
the mechanisms by which cytoskeletal components become rearranged and 
apoptosis is initiated have not been addressed. 
GCV, as well as the related compound ACV, inhibit DNA polymerases α, δ 
and ε(118).  While both GCV and ACV preferentially inhibited DNA polymerase δ, 
GCV was 40 times more potent than ACV(118).  GCV lacks the 2’ carbon in the 
carbohydrate moiety, however the presence of the 3’ carboxy-group allows 
extension of the DNA chain.  Therefore, despite inhibition of DNA polymerases 
during incorporation into the nascent strand of DNA, GCV is not an obligatory chain 
terminator(48;119;120) as is the related compound acyclovir (ACV)(118), which 
lacks the 2’ carbon of deoxyguanosine as well as the 3’ carbon necessary for DNA 
chain elongation(121).   Overexpression of DNA polymerase β (polβ) confers 
resistance to GCV while polβ null fibroblasts are hypersensitive to GCV(122).  Polβ 
plays a role in the DNA repair pathway of base excision repair (BER) suggesting BER 
is initiated in response to GCV.  Furthermore, inhibition of DNA polβ results in 
approximately 1.5-fold increase in GCVTP incorporation suggesting BER removes a 
portion of the incorporated GCVMP into DNA(122).  Despite the removal of GCVMP 
by BER, studies have demonstrated that BER proficient cells retain GCVMP in DNA 
for as long as 48hr post drug washout(92).  This retention of GCVMP in DNA 
suggests that although BER promotes survival in response to GCV by removing it 
from DNA before it can elicit cytotoxicity, the majority of incorporated GCVMP is 
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not recognized as a faulty nucleotide and remains in DNA where it eventually kills 
the cell.   
To begin addressing the consequences of the presence of GCVMP in DNA, 
Thust et al demonstrated that GCV caused both single and double strand DNA 
breaks at clinically achievable concentrations which resulted in apoptosis(123).  
Additionally, they demonstrated that sub-cytotoxic GCV concentrations induced 
sister chromatid exchanges, chromosome breaks, chromosomal translocations, and 
other aberrations during the second cell cycle following GCV treatment whereas 
ACV did not(123-125).  These types of chromosomal abnormalities result from 
aberrant or failed DNA repair suggesting that the DNA damage pathways and 
consequences of DNA repair differ significantly between GCV and ACV.  In light of 
the fact that sister chromatid exchanges arise as a consequence of HR repair(126), 
these results also suggest HR is activated in response to GCV.  In support of this 
hypothesis, studies evaluating yeast strains deficient in DNA repair proteins 
demonstrated that strains deficient in HR proteins are more sensitive to GCV 
indicating that HR is promoting survival in response to GCV(127).  Rubsam et al 
evaluated the metabolism and cell cycle effects of GCV compared to less cytotoxic 
HSV-TK analogs acyclovir (ACV) and 1-β-D-arabinofuranosyl thymine (araT) (Fig. 
1.3).  The comparison of GCV to ACV revealed that the inferior cytotoxicity of ACV 
could be attributed to lower phosphorylation to the triphosphate form compared 
to GCV resulting in lower amounts of the active metabolite and subsequently lower 
incorporation into DNA.  However, compared to GCVTP, araT triphosphate 
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accumulated to a greater extent while its elimination occurred more slowly.  This 
difference in kinetics resulted in a ~500-fold increase in incorporation of araTMP 
into DNA compared to GCVMP at equitoxic concentrations(92).  These results 
suggested a unique mechanism of GCV mediated cytotoxicity compared to araT.   
Rubsam et al also demonstrated that GCV elicits a unique cell cycle 
disruption compared to other nucleoside analogs.  Upon incorporation into DNA, 
most nucleoside analogs including araT interfere strongly with DNA synthesis in the 
first cell cycle after drug addition, however, surviving cells progress through S-phase 
and return to a normal cell cycle distribution(92;128).  This cell cycle pattern implies 
that, while cells have difficulty incorporating analogs such as araT, if they succeed 
the incorporated araT will serve as an adequate substrate for DNA synthesis in later 
cell cycles(92).  In contrast, GCVMP incorporation produces only moderate DNA 
synthesis inhibition thereby permitting cells to eventually complete S-phase and 
undergo cell division.  Upon entry into the second S-phase, cells arrest permanently 
and die(92) suggesting GCVMP is a poor substrate for DNA replication when in the 
template strand of DNA.   
Collectively, these studies have led to the following model for GCV mediated 
cytotoxicity: GCVTP competes with dGTP for incorporation into DNA.  Despite the 
ability to inhibit DNA polymerases(118), GCVMP becomes incorporated into DNA in 
internucleotide linkages(48;92).  The DNA repair pathway of BER removes a fraction 
of GCVMP from DNA which promotes survival(122), while GCV does not activate 
nucleotide excision repair(122) thus demonstrating the specificity of repair 
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pathways activated by GCV.  Following exposure to GCV during S-phase, cells 
subsequently complete DNA replication and the remainder of the cell cycle with 
GCVMP in DNA.  Upon entry into the second S-phase cells permanently arrest and 
eventually undergo cell death by apoptosis(92).  The DNA repair pathway of HR 
attempts to repair GCV induced DNA damage in the second cell cycle, however at 
cytotoxic concentrations HR fails to promote cell survival.  This suggests targeting 
HR pharmacologically will be a novel, mechanism based approach to enhancing the 
cytotoxicity of GCV. Furthermore, the observation that GCV causes cell death 
despite lower incorporation into DNA relative to other HSV-TK substrates suggests a 
better understanding of HR in the context of repairing GCV induced DNA damage 
may reveal the mechanism of the superior cytotoxicity of GCV relative to other 
HSV-TK substrates.    
 
DNA Repair and HR 
Every day a cell in the human body receives an average of over 10,000 DNA 
lesions(129-131).  The cause of this damage occurs from natural processes such as 
metabolism and normal DNA replication as well as from exogenous sources such as 
IR, sunlight, and chemicals such as chemotherapeutic agents.  Of all the possible 
types of lesions to DNA, double strand breaks (DSBs) are the most deleterious(132).  
In order to repair DNA DSBs, the lesion must first be detected by cellular sensors 
such as the MRN complex(133), a heterotrimer consisting of MRE11, RAD50 and 
NBS1.  After detection of a DSB, the MRN complex recruits and activates signal 
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transducers, such as ATM and ATR, which subsequently go on to activate a large 
number proteins involved in cell cycle checkpoints and DNA repair. Upon activation, 
repair proteins then localize to the DNA strand break and facilitate repair.   
Although both ATM and ATR are required for a full checkpoint 
response(134), ATR is not directly activated by the DSB per se, but rather it is 
activated by single stranded DNA generated resection of DNA(134).   Stalling of DNA 
replication also results in formation of single stranded DNA and thus activation of 
ATR(135),  however the downstream targets of ATR such as chk1(136) are required 
for the full DNA damage response(136). 
After detection of a DSB and activation of cell cycle checkpoint proteins, 
cells use two major repair pathways to repair DNA DSBs: non-homologous end 
joining (NHEJ) and HR(132).  NHEJ is a repair pathway that occurs in all phases of 
the cell cycle and repairs DSBs by ligating the broken strands of DNA back together.  
NHEJ is considered a low fidelity DNA repair pathway because any sequence that is 
lost at the break when the damage occurs can be deleted when the strands are 
ligated back together.  HR is a high fidelity DNA repair process that repairs DSBs 
during S and G2 phases of the cell cycle(137) and re-establishes stalled or collapsed 
replication forks (Fig. 1.4)(138).  HR is considered a high fidelity DNA repair process 
because it uses the other chromosome or “sister chromatid” to resynthesize the 
damaged area which prevents any loss of genetic material (Fig. 1.4).   
After activation of HR in response to a DSB in S-phase, DNA surrounding the 
break undergoes 5’ nucleolytic resection creating a 3’ ssDNA overhang.  The 
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resection of the 5’ end of DNA occurs in two phases.  The first phase is resection 
initiation, which is a slow process involving the MRN(139) complex and the 
exonuclease CtIP(140-142).  The second phase occurs more quickly and involves 
BLM helicase(143) and the exonucleases Sgs1, Dna2, and exo1(139;144).  Several 
studies in yeast evaluating the exonucleases involved in both initiation and 
elongation of DNA resection have demonstrated that if one or multiple 
exonucleases are deleted, resection still occurs due to compensation by redundant 
exonucleases(139;140;144;145).  In human cells, however it was demonstrated that 
the deletion or depletion of CtIP and Exo1 results in genomic instability(146), 
thereby demonstrating the importance of resection during HR in mammalian cells.   
After the formation of the ssDNA by resection, the 3’ overhang is coated by 
RPA to prevent the DNA from undergoing nonspecific annealing to other 
ssDNA(138).  In human cells BRCA2 then mediates the polymerization of the HR 
required protein rad51 into a filament that replaces RPA on ssDNA.  In yeast, the 
replacement of RPA with rad51 is mediated by another ssDNA binding protein, 
rad52.  BRCA2 in human cells or rad52 in yeast then facilitate rad51 mediated 
strand invasion of the 3’ overhang into the sister chromatid(138).  The invading 
DNA is then free to anneal to the complementary sequence of the sister chromatid 
which facilitates the resynthesis of any lost DNA sequence due to the break(138).  
The crossover into the sister chromatid and subsequent annealing of the non-
displaced DNA to the sister chromatid results in two DNA structures referred to as 
Holliday junctions which must be resolved correctly after HR is completed.  Failure 
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to properly resolve both Holliday Junctions results in sister chromatid 
exchanges(126), a phenomenon observed in surviving cells treated with GCV thus 
implicating that HR is initiated in response to GCV.  
This dissertation demonstrates that GCV produces more DNA damage than 
the less cytotoxic analog araT.  GCV induced a biphasic DNA damage response with 
the second increase persisting until cell death suggesting the induction of 
unrepairable DNA damage.  Further, GCV and araT activated the DNA damage 
response through different pathways: GCV primarily activated a double strand 
break response where araT primarily activated a stalled replication response.  
Finally, activation of the double strand break response after GCV treatment results 
in the activation of HR which promotes survival in response to GCV.  Collectively, 
these observations suggest that GCV produces unrepairable DNA damage when in 
template DNA leading to the induction of a double strand break response.  In an 
attempt to rescue the cell, HR is initiated to repair this damage.  At sub-toxic 
concentrations of GCV, HR succeeds at rescuing the cell, however it causes 
SCEs(147) in exchange for repairing the DNA damage and resuming DNA 
replication(148).  At cytotoxic concentrations, HR fails to repair the GCV induced 
DNA damage and cell death ensues.  The results of these studies implicate HR in the 
mechanism of GCV mediated cell death, therefore, I proposed that inhibition of HR 
would enhance cytotoxicity of GCV.      
 
 
25
Rationale for KDAC Inhibitors to Improve HSV-TK/GCV Gene Therapy 
HSV-TK is delivered via adenovirus which infects cells by initially binding to 
CAR(67).  Expression levels of CAR correlate with the number of cells transduced 
and cell survival achieved in cell culture models(149;150).  Additionally, 
phosphorylated GCV metabolites are transferred to bystander cells by connexin 
mediated intercellular gap junctional communication(78-80).  The overexpression 
of connexin proteins results in increased sensitivity to GCV(78;79;81).  Therefore, 
simultaneously enhancing the expression of CAR and connexins pharmacologically 
will result in even greater cell tumor cell kill compared to enhancing either alone.  
The presence of SCEs following GCV indicates that the DNA repair pathway of HR is 
activated in response to GCV(123;124;126).  Thus, although improving any of the 
above mentioned aspects of gene therapy would increase tumor cell kill in response 
to GCV, the pharmacological inhibition of HR combined with overexpression of both 
CAR and connexin proteins would provide a multipronged approach for improving 
gene therapy.  Many of the genes involved in the above mentioned processes are 
regulated by lysine deacetylases (KDACs).  KDACs are enzymes that remove an 
acetyl group from lysines and are most known for their deacetylation of histones, a 
modification associated with transcriptional repression.  In addition to 
deacetylating histones it is now appreciated that KDACs deacetylate a wide variety 
of non-histone proteins.   
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Background of KDAC Enzymes 
There are 18 KDAC enzymes grouped into 4 classes based on their sequence 
homology in yeast where they were first identified.  Classes I, II and IV have a 
structurally similar catalytic domain and require a zinc ion for their function(151).  
Class I KDACs include KDAC1-3 and KDAC7 which share sequence homology with 
the yeast protein RPD3(152).  Class I KDACs are ubiquitously expressed, nuclear 
proteins that are thought to be relatively specific to deacetylating histones 
compared to other KDAC classes(152).  Class II KDACs include KDAC4, 6, 7, 9 and 10 
and are homologous with the yeast protein HDA1(152).  These enzymes exhibit 
tissue specific expression, are present in both the nucleus and cytoplasm, and are 
thought to be the KDACs associated with deacetylating many of the known non-
histone KDAC targets.  Class IV KDACs include only KDAC11 which has no yeast 
counterpart and shares sequence homology to both classes I and II KDACs(152).  
Class III KDACs include 7 enzymes referred to as the sirtulins (sirt1-7).  They are 
homologous to the yeast protein Sir2 and differ significantly from the other classes 
of KDAC enzymes in that they depend on NAD+ (nicotinamide adenine 
dinucleotide) to catalyze the deacetylation of lysine(152). 
In addition to changes in gene expression, activity of the KDACs has been 
linked to cell cycle control(153), cell motility(154), metabolism(155), DNA damage 
repair(153;156), and genomic stability(157).  Therefore, it is not surprising that 
aberrant KDAC activity or mutation of KDAC enzymes is associated with many 
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cancers, and that an intensive search for inhibitors of these enzymes has 
commenced(158).   
One of the first compounds demonstrated to inhibit KDAC enzymes was 
Trichostatin A, which is a natural anti-fungal compound isolated from Streptomyces 
hygroscopicus.  Trichostatin A inhibited the growth of murine erythroleukemia cells 
by inducing their differentiation(159).  While investigating the mechanism by which 
this compound inhibited cell growth, an increase in the acetylation of histones was 
observed(160).  Due to high reactivity and instability, Trichostatin A was not 
evaluated clinically for the treatment of cancer(158), however it remains a valuable 
research tool.   Around the same period of time as the discovery of the 
mechanism for Trichostatin A, Paul Marks et al were screening for non-toxic 
detergents generated by the lab of Ronald Breslow, both at the Memorial Sloan 
Kettering Cancer Center, that inhibited the growth of cancer cells.  Following an 
exhaustive search, they discovered a promising compound, suberoylanilide 
hydroxamic acid (SAHA).  Based on the strong antitumor activity demonstrated in 
clinical trials, SAHA received FDA approval in 2006 under the generic name 
Vorinostat for the treatment of patients with cutaneous T-cell lymphoma who have 
failed other treatments(161).  SAHA is structurally similar to Trichostatin A and 
similar to Trichostatin A, the mechanism underlying SAHA mediated inhibition of 
tumor cell growth is  via  inhibition of class I and II KDAC enzymes(162).   
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Pharmacology of Vorinostat (SAHA) 
SAHA became the first FDA approved KDAC inhibitor, which inhibits the 
enzymes through the reversible binding of the catalytic site of KDAC 
enzymes(158;163).  Structurally, SAHA contains a phenyl group and a hydroxamic 
acid group connected by an aliphatic chain (Fig. 1.5).  The phenyl group of SAHA 
binds the outside of the KDAC enzyme pocket while the aliphatic chain and 
hydroxamic acid moieties bind in the enzyme pocket.  The hydroxamic acid moiety 
is positioned such that it can bind the zinc ion within the enzyme pocket which is 
used by KDAC enzymes to catalyze the deacetylation of lysines(158;163).   
SAHA inhibits all class I KDACs (KDAC1, 2, 3, 8) and one class II KDAC 
(KDAC6)(164) at micromolar concentrations(158).  SAHA is administered orally and 
is 43% bioavailable following 200 or 400mg doses(158;165).  While the absorption 
of SAHA can be delayed in the presence of food high in fat, this does not appear to 
be clinically meaningful(166).  The maximum tolerated dose of SAHA is 400mg/day 
whether given as a single 400mg dose or two.  SAHA exhibits linear 
pharmacokinetics and a half life of approximately 91.6 to 127 minutes following an 
oral dose(165).  SAHA is 71% bound to plasma proteins with serum concentrations 
ranging from 2 to 200 µmol/L(167) and is well distributed throughout the body 
even crossing the blood brain barrier in mouse models(168) where it can reach 
therapeutic concentrations within the CNS(169).  SAHA is not metabolized by P450 
enzymes therefore it is not expected to alter the metabolism of other 
pharmacological agents that inhibit or induce P450 enzymes.  Instead, SAHA is 
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eliminated directly by phase II metabolism routes where it first undergoes 
glucuronidation followed by β-oxidation to the inactive metabolites vorinostat 
glucuronide and 4-anilino-4-oxobutanoic acid. Less than 1% of active SAHA is 
recovered in the urine, thus indicating that metabolism is the primary mechanism 
of elimination(165-167).  Major dose limiting toxicities include anorexia, diarrhea, 
dehydration, and fatigue.  Other side effects include vomiting, hyperglycemia, and 
hematological toxicities (anemia and thrombocytopenia).  The only drugs 
contraindicated with SAHA are coumarin derived anticoagulants(165). 
 
4-Phenylbutyrate (4-BP) and Valproic Acid (VPA) as KDAC Inhibitors 
KDACs had already emerged as promising target for the treatment of cancer 
during the time that SAHA was being developed, thus a search ensued for existing 
natural products and pharmacologic agents that inhibited KDAC enzymes.  Two 
such compounds are 4-phenylbutyrate (4-BP) and valproic acid (VPA).  4-BP is a 
natural product generated by anaerobic metabolism of fatty acids by intestinal flora 
and is hypothesized to be protective against colon cancer(170).  VPA is used as an 
antiseizure medication where it works by slowing the recovery of sodium channels 
thereby preventing their seizure associated repeated firing(13).  Since sodium 
channels have been implicated in processes such as cell adhesion in many cancer 
types(171), the activity of VPA on KDAC enzymes cannot be definitively implicated 
as the mechanism of antitumor activity observed.  Chinnaiyan, et al hypothesized 
that VPA would be a valuable KDAC inhibitor for glioblastoma, a tumor type that is 
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protected from most chemotherapeutic agents by the blood brain barrier(172).  
The ability of antiepileptic medications such as VPA to cross the blood brain barrier 
is well established(13) and Chinnaiyan, et al hypothesized that CNS toxicities due to 
non-KDAC activities of VPA are a surrogate marker of VPA activity(172).  It is now 
appreciated that SAHA readily crosses the blood brain barrier(168;169) and as such 
it provides a more potent and specific KDAC inhibitor for evaluation in CNS 
malignancies.  Furthermore, SAHA is active at nanomolar and micromolar 
concentrations in cell culture whereas both 4-BP and VPA must be administered at 
high concentrations (milimolar range) in order to observe KDAC activity. Despite 
these limitations, studies performed with VPA and 4-PB have  provided valuable 
information for the validation of KDAC enzymes as a target for the treatment of 
cancer, particularly in a gene therapy setting(89-91). 
 
KDAC Inhibitors and Gene Therapy 
KDAC inhibitors are widely known for their ability to inhibit the 
deacetylation of histones resulting in histone hyperacetylation and increased gene 
transcription(152;173).  In light of the fact that several processes involved in 
determining the efficacy of HSV-TK/GCV gene therapy depend on transcription 
levels of key proteins such as CAR(67), connexins(78-80;82;84), and the virally 
delivered HSV-TK itself(68;174), coupled with the fact that KDAC inhibition leads to 
an increase in transcription of many genes, several groups have investigated KDAC 
inhibitors in combination with HSV-TK/GCV gene therapy. Kothari et al 
31
demonstrated that VPA increased the expression of CAR and subsequently 
increased the transduction efficiency by adenovirus, substantially increased the 
expression of an HSV-TK/GFP fusion protein, and produced a reduction of tumor 
size in a mouse xenograft model(91).  In addition to increasing the number of viral 
particles infecting each cell, Ammerpohl et al demonstrated that VPA also increases 
the expression of virally delivered genes under a CMV promoter(89).  These studies 
demonstrate that VPA has the potential to increase HSV-TK expression by multiple 
mechanisms.  Additionally, Asklund et al demonstrated that 4-phenylbutyrate 
increases gap junctional communication by increasing the expression of connexin 
43(90).  Collectively, these studies demonstrate that combination therapy with 
KDAC inhibitors and HSV-TK/GCV gene therapy is a promising approach for future 
studies both in vitro(89;90) and in vivo(91) and warrant further study.  These 
studies did not however examine whether KDAC inhibitors are capable of proving 
any additional benefit to HSV-TK/GCV gene therapy by enhancing the cytotoxicity of 
GCV.     
 
KDAC Inhibitors and DNA Damage Repair 
GCV treatment in HSV-TK expressing cells results in DNA strand breaks(123) 
and studies in yeast demonstrate that HR promotes survival in response to 
GCV(127) suggesting HR may repair these breaks.  Therefore, if KDAC inhibitors 
could pharmacologically inhibit HR they may provide yet another improvement of 
HSV-TK/GCV gene therapy approaches.  Chinnaiyan et al demonstrated that the 
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accumulation of γH2AX and 53BP1 foci to sites of DNA damage persist in response 
to IR if cells were pretreated with VPA(172).  Their continued presence could be 
explained by persistent DNA damage due to KDAC mediated inhibition of DNA 
repair mechanisms.  While this study suggests DNA repair may be inhibited by KDAC 
inhibition, it does not directly demonstrate that DNA damage persists or provide 
insight as to which DNA repair pathway is inhibited.   
To address the potential role of KDAC inhibition on inhibiting HR, 
Adimoolam et al evaluated the effects on HR after IR in cells that were pretreated 
with the KDAC inhibitor PCI-24781.  These studies demonstrated that the inhibition 
of KDACs decreased mRNA levels of several required HR proteins including BRCA1, 
BRCA2 and rad51.  A concentration and time dependent decrease in rad51 protein 
expression was also noted both in cell culture models and in mouse xenograft 
studies.  Importantly, the authors noted that pre-incubation of cells with a KDAC 
inhibitor sensitized cells to IR, blocked rad51 foci formation after IR, and decreased 
the number of HR events measured in a cell based assay(156).  Together these 
results suggest that KDAC inhibitors inhibit HR by decreasing the expression of HR 
required proteins and associated repair activity.   
The inhibition of KDACs has also been demonstrated to affect HR by 
mechanisms other than altering transcription.  KDAC inhibition with VPA has been 
demonstrated to counteract ATR activity, inhibit recruitment of HR proteins to an 
induced DNA DSB, and to slow DNA end resection during HR-mediated repair of an 
enzymatically induced DSB(175).  Other studies have demonstrated that VPA 
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inhibits the deacetylation of CtIP, a required exonuclease for HR, which promotes 
its degradation(175).  Furthermore, it has been demonstrated that the acetylation 
status of exo1, another exonuclease involved in HR, can alter the function of this 
protein(175).  Therefore, KDAC enzymes perform several regulatory functions in 
DNA end resection during HR.  Previous studies have demonstrated that the 
depletion of CtIP and exo1 results in genomic instability(146).  The regulation of 
CtIP and exo1 by KDAC enzymes demonstrates a role for KDAC enzymes in the 
maintenance of genomic instability through regulation of HR.     
To address which KDAC enzymes are involved in the regulation of genomic 
stability, Bhaskara et al demonstrated that knockout of KDAC3 in murine fibroblasts 
results in cells that undergo fewer HR and NHEJ events after an enzymatically 
induced DNA DSB.  KDAC3 null cells also contain an increased number of 
chromosomal aberrations(153;157). Importantly, KDAC3 is a class I deacetylase and 
as such can be inhibited by SAHA(164). Therefore, SAHA may be capable of 
inhibiting DNA repair in tumor cells containing HSV-TK when combined with an 
agent such as GCV.  Furthermore, previous reports evaluating DNA replication in 
the presence of SAHA noted a slowing of DNA replication, a phenomenon that can 
be recapitulated by depletion of KDAC3(176).  GCV treatment results in moderate 
stalling of DNA synthesis during incorporation into DNA(92).  Therefore, strong DNA 
replication inhibition may be observed by the combination of GCV and SAHA.  
Stalling of DNA replication activates an ATR mediated DNA damage response(135) 
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thus providing another mechanism of DNA repair activation in response to GCV and 
SAHA.   
Collectively, these studies strongly suggest that KDAC inhibitors will 
synergistically enhance the efficacy of DNA damaging agents by inhibiting repair.  
Indeed, KDAC inhibitors have demonstrated synergistic tumor cell kill when 
combined with a variety of DNA damaging agents including doxorubicin(177;178), 
etoposide(178), 5-fluorouracil and fluorodeoxyuridine(179), cisplatin, and 
melphalan(180).  Evidence that GCV may induce DNA damage that must be 
repaired by HR(127) suggests that KDAC inhibitors such as SAHA may synergize with 
GCV by inhibiting the repair of GCV induced DNA damage by HR.  Furthermore, the 
potential for enhancing adenoviral HSV-TK gene delivery, HSV-TK expression, and 
gap junctional communication while simultaneously enhancing cell kill makes the 
combination of KDAC inhibitors with HSV-TK/GCV gene therapy an attractive 
approach for selectively targeting tumors.   
The goal of chapter III of this dissertation is to determine whether the KDAC 
inhibitor SAHA can inhibit the HR repair of GCV induced DNA damage and elicit 
synergistic cell kill.  Using U251 glioblastoma cells expressing HSV-TK, I demonstrate 
that coincubation with GCV and SAHA results in enhanced cytotoxicity.  Using a cell 
based assay that detects HR events I demonstrate that SAHA inhibits HR activity.  
Additionally, SAHA decreases the protein levels of the HR required proteins rad51 
and CtIP.  Furthermore, SAHA completely blocks rad51 foci formation in response 
to GCV.  Finally, I demonstrate that GCV and SAHA coincubation results in 
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synergistic cytotoxicity in HR proficient CHO cells while only additive cytotoxicity in 
HR deficient cells.  Therefore, synergy observed between GCV and SAHA is due to 
the inhibition of HR by SAHA thereby preventing repair of GCV induced DNA lesions.   
 
Conclusions 
The overall goal of this dissertation is to investigate new approaches to 
improve HSV-TK/GCV gene therapy by enhancing the efficacy of GCV.  These 
findings identify a novel drug combination with HSV-TK gene therapy and 
potentially identify new mechanisms for drug targeting in tumor cells.  This 
information will ultimately provide novel approaches in animal studies and 
potentially clinical trials.   
 Previous studies have demonstrated that GCV is incorporated into DNA and 
induces chromosomal aberrations such as sister chromatid exchanges (SCEs) and 
chromosomal breaks(123-125).  However, the cellular response preceding the 
generation of SCE’s in response to GCV has not been determined.  I hypothesize 
that GCV will activate DNA damage repair pathways differently than less cytotoxic 
analogs such as araT.  Furthermore, I hypothesize that GCV will activate the DNA 
damage response to a greater extent than araT despite lower incorporation of GCV 
into DNA.   
After DNA damage has occurred, the DNA damage response is activated by 
the kinases ATM and ATR.  ATR is activated by single stranded DNA which often 
forms from stalled replication forks(135).  ATM is activated primarily by DSBs which 
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can occur by damaging agents such as IR or collapsed replication forks(134), that 
result from the inability to resume DNA synthesis after stalling of DNA 
replication(181;182).  Chapter II demonstrates that while both GCV and araT 
activate ATR and ATM, the kinetics of activation differ significantly.  ATR activation 
in response to GCV is detected at a consistent level at all times evaluated during 
drug incubation and persists after the removal of GCV.  Conversely, araT induces a 
strong, transient ATR response during drug incubation followed by a persistent low 
response after removal of araT.  AraT also induces a weak persistent activation of 
ATM during drug incubation and after its removal.  In response to GCV, ATM is 
strongly activated 24 hours following the addition of GCV, a time coincident to 
entry into the second cell cycle after the addition of drug where they subsequently 
arrest permanently and die.  This is consistent with the hypothesis that, although 
both GCV and araT cause DNA replication stress, araT inhibits DNA replication while 
being incorporated into DNA.   Conversely, GCV induces unrepairable DNA damage 
when in the DNA template.   
In addition to the ATM and ATR kinase pathways activated in response to 
GCV and araT chapter II demonstrates that both GCV and araT induce rad51 foci 
formation thus indicating HR is activated in response to both drugs.  Additionally, 
there was no significant difference in the percent of rad51 positive cells or the 
number of rad51 foci per positive cell following GCV or araT treatment.  Therefore, 
rad51 foci formation cannot explain the differences in cytotoxicity observed with 
GCV and araT.  The observation that HR is activated in response to GCV supports 
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the suggestion that SCEs observed after low dose GCV occur as a result of HR.  
Therefore, the observation that araT activates HR was surprising given that 
previous studies have demonstrated that another less toxic substrate for HSV-TK, 
ACV, did not induce SCEs(123-125).  This unexpected observation that both GCV 
and araT activate HR coupled with the observation that only GCV causes DSBs 
supports the hypothesis that GCV is inducing a unique, unrepairable DNA lesion 
whereas other HSV-TK substrates induce cell death by overwhelming the DNA 
damage response with potentially repairable DNA lesions.   
The presence of rad51 foci and SCEs in response to GCV indicate the 
activation of HR, however, they do not indicate whether HR is promoting cell 
survival or cell death.  Evidence of HR promoting cell survival in response to GCV 
has been documented in yeast(127).  I hypothesize that HR promotes cell survival in 
response to GCV in mammalian cells.  Furthermore, I hypothesize that 
pharmacologic inhibition of HR will produce synergistic cytotoxicity with GCV.  To 
test the hypothesis that HR promotes survival in response to GCV, I have evaluated 
GCV sensitivity in matched CHO cell lines that are either proficient or deficient in 
HR.  Using this approach, chapter III demonstrates that HR promotes cell survival in 
response to GCV suggesting that inhibition of HR will enhance the cytotoxicity of 
GCV.  While there are no direct or specific pharmacologic inhibitors of HR, the KDAC 
inhibitor PCI-24781 was demonstrated to inhibit HR by decreasing the expression of 
HR required proteins such as rad51(156).  Chapter III of this dissertation 
demonstrates that the FDA approved KDAC inhibitor SAHA also inhibits HR.  
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Furthermore, chapter III demonstrates that SAHA decreases the expression of HR 
required proteins such as rad51, inhibits HR activity in a cell based assay, and blocks 
rad51 foci formation in response to GCV.  Finally, chapter III demonstrates that the 
combination of GCV and SAHA results in synergistic cytotoxicity in HR proficient 
cells and only additive cytotoxicity in HR deficient cells.  These results suggest that 
HR is promoting cellular survival in response to GCV and pharmacological inhibition 
of HR with SAHA results in synergistic cell death.     
Collectively, the results described within this dissertation demonstrate the 
mechanistic differences in activation of DNA damage repair pathways in response 
to GCV and a less cytotoxic drug, araT, which provides insight into the mechanism 
underlying the superior cytotoxicity of GCV compared to other HSV-TK substrates.  
Additionally, the results reveal the DNA repair pathway of HR is activated by GCV 
and the role of HR is to promote cell survival in response to GCV.  The observation 
that HR promotes cell survival in response to GCV identifies HR inhibition as a 
unique mechanism based approach that may enhance gene therapy effectiveness.  
Furthermore, results described within this dissertation provide the field with a 
previously unappreciated role for the KDAC inhibitor SAHA and its ability to inhibit 
HR.  Finally, the results uncover the novel mechanism based drug combination of 
GCV and SAHA.  Based on the observations in this dissertation, future in vivo studies 
evaluating HSV-TK/GCV and SAHA could demonstrate a promising new direction for 
suicide gene therapy.   
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Figure 1.1 Development of ACV Pt. 1.  A.) araA was the first antiviral marketed in 
the United States.  B.) 2,6-diaminopurine was used to treat leukemia.  It was 
known to  have antivrial activity as well but was not used due to high toxicity.   
C.) Burroughs Wellcome Company combined the arabinose  sugar with 2,6-
diaminopurine (2,6-diaminopurine  arabinoside)  and observed it was more 
selective for inhibiting  viruses compared to AraA but not as efficacious. 
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 Figure 1.4 Homologous recombination. After a DNA double strand break, DNA 
is resected in a 5’ to 3’ direction.  This creates 3’ overhangs that invade the 
sister chromatid and are used as primers for DNA replication machinery to 
resynthesize the damaged region of DNA.  After resynthesis of the damaged 
region, the sister chromatids must be properly resolved away from each other.  
If they are resolved incorrectly, sister chromatid exchanges occur.     
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1 - DNA double strand break from  
sources such as radiation, free 
radicals, chemotherapeutic  
drugs, etc 
 
2 - Detection of damage by the 
MRE11, RAD50, NBS1 (MRN) 
complex triggering  checkpoint 
activation (ATM activation) 
 
5 - ssDNA is coated by RPA until 
displaced by rad51 
7 - The 3’ overhang serves as a template  
for resuming DNA synthesis 
6 - Rad51 mediates the invasion of the 
 3’ overhang into the sister chromatid 
8 - The displaced strand of the sister  
chromatid serves as a template for  
synthesis of any lost DNA sequence 
9 - If resolved correctly the damaged DNA 
 end will have a “patch product” of newly 
synthesized DNA replacing the break 
4 - 5’ DNA end resection by the MRN  
complex, CtIP and EXO1 
3 - γH2AX marks the damaged 
area and  facilitates repair 
protein recruitment 
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Chapter II 
 
Unrepairable DNA Double Strand Breaks Initiate Cytotoxicity with HSV-TK/Ganciclovir 
 
 
Summary 
 
The herpes simplex virus thymidine kinase (HSV-TK) is the most widely used suicide gene 
in cancer gene therapy due to its superior anticancer activity with ganciclovir compared 
to other HSV-TK substrates, such as 1-β-D-arabinofuranosyl thymine (araT).   We have 
evaluated the role of DNA damage as a mechanism for the superiority of GCV.  Using γ-
H2AX foci as an indicator of DNA damage, GCV induced > 7-fold more foci than araT at 
similarly cytotoxic concentrations.  The number of foci decreased after removal of either 
drug, followed by an increase in Rad51 foci indicating that (HRR) was used to repair this 
damage.  Notably, only GCV produced a late and persistent increase in γ-H2AX foci 
demonstrating the induction of unrepairable DNA damage.  Both drugs induced the ATR 
damage response pathway, as evidenced by Chk1 activation.  However, GCV resulted in 
greater activation of ATM, which coincided with the late induction of γ-H2AX foci, 
demonstrating the presence of DNA double strand breaks (DSBs).  The increase in DSBs 
after Rad51 induction suggested that they occurred as a result of a failed attempt at 
homologous recombination repair (HRR).   These data demonstrate that the late and 
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unrepairable DSBs observed uniquely with GCV account for its superior cytotoxicity and 
further suggest that inhibition of HRR will enhance cytotoxicity with HSV-TK/GCV. 
 
Introduction 
While the initial goal of suicide gene therapy for cancer treatment was to 
maintain or increase tumor cell killing while sparing normal tissue toxicity, this approach 
also provided an opportunity to discover new drugs with potentially novel mechanisms 
of action that would lead to greater antitumor efficacy(1).  In addition, identifying the 
mechanism by which drugs used in suicide gene therapy elicit cytotoxicity may provide 
new, novel drug combinations that can enhance gene therapy without compromising its 
selectivity.  One of the most widely used and studied suicide gene therapy approaches 
utilizes the herpes simplex virus thymidine kinase (HSV-TK) to activate the antiviral drug 
ganciclovir (GCV) to  produce a non-traditional toxic metabolite with the potential for a 
novel mechanism of action leading to greater cancer cell killing.  Indeed HSV-TK/GCV 
exhibits unique kinetics of cell killing and a remarkably mild effect on DNA synthesis that 
distinguishes it from traditional nucleoside analogs.  The resulting excellent antitumor 
activity in preclinical studies has prompted numerous clinical trials, with promising 
results in a combination approach in patients with prostate cancer(2-4). 
HSV-TK/GCV is the most widely used suicide gene therapy approach both in vitro 
and in vivo.  However, little attention has been focused on the mechanism by which it 
produces cell death.  Similar to other nucleoside analogs, cytotoxicity requires activation 
of GCV (mediated by HSV-TK) to GCV 5’-triphosphate, which competes with dGTP for 
incorporation into DNA in internucleotide linkages(5;6).  While GCV shares this basic 
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mechanism of cytotoxicity with other HSV-TK substrates, including the efficacious 
antivirals acyclovir (ACV) and 1-β-D-arabinofuranosylthymine (araT), GCV induces multi-
log cell killing at sub-micromolar concentrations, whereas ACV and araT were weakly 
cytotoxic at concentrations >100 µM(5).   We have demonstrated previously that limited 
phosphorylation of ACV likely accounts for its poor cytotoxicity.  However, araT is 
phosphorylated and incorporated to a greater degree than GCV, thus the reason for the 
inferiority of araT is not clear. 
A few studies have attempted to address the mechanism by which GCV causes 
cell death.  A study in B16 murine melanoma cells indicated GCV induced a 
morphological change in cells due to the reorganization of components of the 
cytoskeleton as well as an accumulation of cells in G2/M after a 48-72 hr incubation(7).  
It has also been reported that GCV treatment results in a decline in Bcl-2 levels and 
activation of caspases, leading to apoptosis(8).  While these studies highlight pathways 
utilized by GCV that lead to cell death, they do not address the mechanism by which 
GCV is many logs more cytotoxic than other HSV-TK substrates.  To begin addressing the 
consequences of GCV in DNA, Thust et. al demonstrated that GCV induced sister 
chromatid exchanges and chromosome breaks and translocations, whereas another 
substrate for HSV-TK, ACV, did not(9;10).  In light of the fact that sister chromatid 
exchanges arise as a consequence of HRR (HRR),(11) these results suggest that DNA 
damage and pathways involved in its repair differ significantly between these drugs. 
In a comparison of the events that lead to cytotoxicity for GCV and araT, we 
reported a unique manner of delayed cell death in response to GCV(5).  Cells completed 
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one cell division after incubation with GCV.  However, when they attempted to progress 
through the cell cycle for a second time, they were blocked in S phase where they 
remained until cell death occurred.  In contrast, cells treated with araT accumulated in S 
phase and growth was inhibited for at least two days after drug washout, but 
subsequently cells progressed through the cell cycle and the cell number increased.  This 
suggests that, with GCV treatment, an event occurring during this second round of DNA 
replication caused cells to permanently arrest in S phase, resulting in cell death whereas 
araT produced greater disruption during the first S-phase. 
In order to further understand the mechanisms by which these drugs elicited 
cytotoxicity, we evaluated the consequences of DNA incorporation for GCV and araT.  
We hypothesized that the distinct cell cycle kinetics of cell death with GCV and araT 
would result in measurable differences in the induction of a DNA damage response.  
Therefore, we wished to measure the extent and time course of DNA damage and its 
repair following treatment with GCV compared to araT.  In addition, we evaluated a role 
for HRR (HRR), as our previous studies in a yeast model indicated this repair pathway 
could rescue cells from GCV cytotoxicity,(12) and prior reports of sister chromatid 
exchanges promoted by GCV(9;10) suggested a role for HRR.  Furthermore, we 
evaluated the extent to which each drug activated the two major DNA damage response 
pathways, mediated by ATR and ATM.  Collectively, the results demonstrate a dramatic 
difference in the type and degree of DNA damage with GCV relative to araT, leading to 
distinct mechanisms of cell death. 
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Materials and Methods 
Cell Culture 
U251 human glioblastoma cells were maintained in exponential growth in RPMI 1640 
medium supplemented with 10% calf serum (GIBCO, Grand Island, NY) and L-glutamine 
(Fisher Scientific, Pittsburgh, PA) in a humidified atmosphere at 37ºC with 5% CO2.   For 
stable expression of HSV-TK, U251 cells were transduced with a retroviral vector 
encoding the herpes simplex virus type 1 thymidine kinase, using the retrovirus long 
terminal repeat for a promoter, and the neomycin resistance gene for selection as 
previously described(5).  HSV-TK-expressing cells were selected with G418, and 
individual clones were expanded and maintained in medium containing G418.  HSV-TK 
expression was determined by incubating cells with GCV and measuring phosphorylated 
GCV metabolites in cell lysates. 
 
Analysis of γ-H2AX foci formation by laser scanning confocal microscopy 
Cells were grown on chambered slides for 48 hr prior to drug addition.  After incubation 
with drug, the cells were washed with PBS and then fixed and permeabilized with 
acetone/methanol (50:50 v/v) for 10 min.  The fixed cells were then washed with PBS, 
blocked with 10% goat serum for 1 h, incubated with γ-H2AX primary antibody (1:400 
dilution; Upstate, Charlottesville, VA) for 1 h, washed, incubated with AlexaFluor 488 
conjugated goat anti-rabbit secondary antibody (1:200 dilution; Molecular Probes, 
Eugene, OR) for 1 h, washed and mounted with ProLong antifade kit (Molecular Probes, 
Eugene, OR).  Slides were imaged with a Zeiss LSM510 confocal microscope using a 60x 
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objective lens.  Images of representative cell populations were captured, and γ-H2AX 
foci were counted visually.  At least 5 - 16 cells per well were counted with triplicate 
wells per condition, and each experiment was performed at least three times. 
 
Analysis of Rad51 foci formation by laser scanning confocal microscopy 
 
Cells were grown on chambered slides for 48 hours prior to drug addition.  Drug was 
added for 24 hours unless otherwise noted.  At specified time points, cells were washed 
with PBS and permeabilized with Triton-X buffer (0.5% Triton, 20mM Hepes, 50 mM 
NaCl, 3 mM KCl, 300mM Sucrose) for 5 min.  Permeabilized cells were then fixed with 
paraformaldehyde solution (3% PFA, 2% sucrose, 1X PBS) for 30 min, washed 3 times for 
10 minutes in wash buffer (0.5% NP40, 0.3% Sodium Azide, 1X PBS), blocked with 10% 
goat serum for 1 hour, and incubated with rabbit anti-Rad51 primary antibody (1:1600 
dilution; Calbiochem, La Jolla, CA) for 1.5 hours.  Cells were then washed 3 times in wash 
buffer, incubated with AlexaFluor 488 conjugated goat anti-rabbit secondary antibody 
(1:2000 dilution; Molecular Probes, Eugene, OR) for 1 hour, washed 3 times in wash 
buffer then washed with DAPI (.1μg/ml DAPI in 1X PBS) and mounted with ProLong 
antifade kit (Molecular Probes, Eugene, OR).  Slides were imaged with an Olympus 
FV500 confocal microscope using a 100x objective lens.  Images of representative cell 
populations were captured, and Rad51 positive cells were scored visually (cells with >10 
foci were considered positive).  At least 63 - 260 cells per well were scored with 
triplicate wells per condition, and each experiment was performed at least three times.  
Statistical significance was determined using a t-test. 
 
74
Analysis of γ-H2AX and BrdUrd immunostaining by laser scanning confocal microscopy 
Cells were grown on chambered slides for 48 hr prior to drug addition.   Cells were 
incubated with 30 µM BrdUrd for 30 minutes at the conclusion of drug incubation.  Cells 
were fixed, permeabilized, and stained for γ-H2AX as described above, using AlexaFluor 
594 conjugated goat anti-rabbit secondary antibody.  After the final wash, antibody 
complexes were fixed with 3.7% paraformaldehyde in PBS for 10 minutes.  Cells were 
treated with 2.5 N HCl for 30 minutes at 37°C and stained with AlexaFluor 488 mouse 
anti-BrdUrd conjugate (1:20 dilution, BD Pharmingen, San Jose, CA) for 1 hr.  Slides were 
mounted and imaged as described above.   At least 14 - 58 cells per well were counted 
with triplicate wells for each condition, and the experiment was performed at least 
twice.  Percent positive cells were calculated as the number of cells positive for the 
indicated marker (BrdUrd or γ-H2AX) divided by the total number of cells examined.  
Percent γ-H2AX positive cells that were also positive for BrdUrd was calculated as the 
number of cells positive for both  markers divided by the number of BrdUrd positive 
cells. 
 
 
Analysis of γ-H2AX expression by flow cytometry 
After drug incubation, cells were harvested by trypsinization and washed with PBS.  The 
pellets were resuspended in ice-cold PBS followed by the addition of cold 2% 
paraformaldehyde.  Samples were then incubated at 4ºC for a minimum of 30 min.  
Fixed samples were centrifuged and the pellets were resuspended in PBS containing 
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0.5% Tween 20 and incubated at 3ºC for 15 min. PBS containing 0.5% Tween 20 and 5% 
serum (PBT) was added followed by centrifugation.  Pellets were then resuspended in 
PBT.  Anti-γ-H2AX antibody was added to each sample and incubated for 45 min at room 
temperature and then washed with PBT.  The pellets were then resuspended in anti-
rabbit phycoerythrin conjugate antibody (Sigma Chemical Co, St. Louis, MO) and 
incubated for 45 min at room temperature.  Samples were washed with PBT and 
resuspended in 7-Amino Actinomycin D (7-AAD) (Molecular Probes, Eugene OR) and 
incubated at room temperature for at least 30 min prior to flow cytometric analysis.  
Analysis was performed on BD FacsCalibur at the University of Michigan Flow Cytometry 
Core Facility.  At least 10,000 cells were evaluated for each condition, and the 
experiment was performed at least three times. 
Western Blot 
All western blots for Chk1(Cell Signaling), pChk1(Ser317)(Cell Signaling), and actin 
(Calbiochem) were performed on 10% polyacrylamide gels according to standard 
protocols.  Western blots for ATM (Epitomics) and pATM(Ser1982) (Epitomics) were 
performed as described above with exceptions:  resolving gels were 6% polyacrylamide, 
transfer buffer contained 10% methanol and transfers were carried out at 300 mAmps 
overnight at 4°C.  All secondary antibodies were HRP conjugated and from Santa Cruz.  
Phospho-ATM bands were quantitated using Image J software from the NIH, version 
1.41. 
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Results 
γ-H2AX foci were used to identify sites of DNA damage, such as DNA double 
strand breaks (DSBs) or stalled replication forks(13-17).  Measurement of γ-H2AX foci 
demonstrated a dose-dependent increase in γ-H2AX foci after a 24 hr incubation with 
GCV in U251tk cells, relative to untreated control cells (Fig. 2.1A and B).  Incubation with 
the non-cytotoxic IC10 (0.03 µM) for GCV resulted in a 4.4-fold increase (±2.9) in γ-H2AX 
foci which was not significantly different from control (p = 0.3).  Treatment with the IC50 
(0.05 µM) or IC90 (0.2 µM) for GCV, however, significantly increased the number of γ-
H2AX foci per cell (14.3 ± 6.3 fold and 24.4 ± 6.8 fold, respectively; p<0.001) indicating a 
substantial increase in DNA damage. 
γ-H2AX expression was also assayed by flow cytometry in order to evaluate the 
effect of increasing drug concentrations on total γ-H2AX fluorescence.  In untreated 
control cells, only 2% of the cells expressed detectable levels of γ-H2AX.  Treatment with 
0.2 and 1 µM GCV (>IC90) for 24 hr significantly increased the percentage of cells 
expressing γ-H2AX to 20% (p<0.01) and 59% (p<0.001), respectively (Figs 2.2A and 2.2B).  
Thus, two different independent methods have demonstrated an increase in γ-H2AX 
with increasing GCV concentration.  Because quantifying the number of sites of DNA 
damage per cell provided a more definitive assessment of the extent of DNA damage 
compared to measuring simply the percentage of cells positive for γ-H2AX, subsequent 
experiments measured DNA damage using in situ immunohistochemistry. 
Previously we have demonstrated that, although cell cycle progression is slowed 
during incubation with GCV, cells completed S-phase and divided.  The lethal insult 
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occurred during the second S-phase when cells were permanently arrested.   Therefore 
we hypothesized that the DNA damage observed during GCV incubation (Fig. 2.1) was 
repaired enabling completion of the first S-phase, but additional DNA damage was 
incurred during the second S-phase.  To test this hypothesis, U251tk cells were treated 
with either non-toxic (IC10) or cytotoxic (IC50, IC90) concentrations of GCV for 24 hr and 
assayed for γ-H2AX foci formation (Fig 2.3).   At each concentration of GCV tested, an 
increase in foci was apparent within 12 hr after drug addition, continued through the 
end of the incubation, and decreased by 12 hr after drug washout.  At the IC10 for GCV, 
the number of foci was <5-fold greater than control levels throughout the 48 hr post-
washout period.  The two cytotoxic concentrations of GCV produced a considerably 
greater number of γ-H2AX foci, increasing to ~15 – 25-fold higher than control at the 
conclusion of the incubation.  This high level of DNA damage appeared to be repaired, 
as the number of γ-H2AX foci decreased to <5-fold more than control by 12 hr after drug 
washout without a substantial decrease in cell number.  However, after 24 hr following 
washout of GCV at the IC50 or IC90, the number of foci increased to greater than 10-fold 
over control, at which point massive loss of cells was apparent. 
In view of the fact that cells treated with GCV arrest permanently during the 
second round of DNA replication following drug incubation,(5) we wished to verify that 
the presence of DNA damage at that time, indicated by γ-H2AX foci, predominated in S 
phase cells. Cells were treated with either no drug (control) or GCV (IC10, IC50 and IC90) 
for 24 hr, then incubated with 5-bromo-2’-deoxyuridine (BrdUrd) for 30 min to identify 
cells actively replicating DNA, followed by staining for both BrdUrd in DNA and γ-H2AX.  
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At drug washout (0 hr), the majority of γ-H2AX positive cells were in S phase, as 
indicated by BrdUrd incorporation, with a decrease to approximately one-quarter to 
one-half of γ-H2AX positive cells in S-phase by 24 hr after GCV washout (Table 2.1).  At 
48 hr after washout of GCV at its IC50, more than 70% of γ-H2AX labeled cells were in S-
phase.  Although cells treated with the IC90 for GCV were not positive for BrdUrd at this 
time point, previously we have demonstrated that these cells are in S phase (propidium 
iodide staining) but with DNA synthesis decreased by more than 80%(5;18).   Thus, the 
large increases in γ-H2AX foci observed with cytotoxic concentrations of GCV occurred 
primarily in S-phase cells. In particular, cells dying in the second S-phase incurred 
significant DNA damage. 
For comparison, we measured the effect of araT on γ-H2AX foci formation.  After 
incubation of U251tk cells with the IC10, IC50, and IC80 for araT (1 µM, 11 µM, and 100 
µM, respectively) for 24 hr, a concentration-dependent increase in γ-H2AX foci was 
observed (Fig 2.4A and 2.4B).  However, the magnitude of foci formation was 
considerably less with araT (2 - 3.5-fold increase compared to control) relative to a 
similarly or less cytotoxic concentration of GCV (15 - 25-fold increase at IC50 and IC90, 
respectively; Fig 2.1B). 
Evaluation of the kinetics of foci formation with araT (IC50) during a 24 hr 
incubation revealed a small increase in the number of γ-H2AX foci (2.25-fold greater 
than control).  The number of foci decreased by 12 hr after drug washout and remained 
slightly higher (approximately 1.7-fold) compared to control cells.  No further increase 
was observed for up to 96 hr after washout (Fig. 2.5B).  Thus both the degree and 
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pattern of DNA damage was substantially different with araT relative to GCV.  The 
number of foci in response to araT was not greater than that produced by the IC10 (non-
cytotoxic) for GCV, suggesting that the damage indicated by γ-H2AX foci was not 
sufficient to account for the cytotoxicity of araT. 
The kinetics of γ-H2AX foci formation observed with cytotoxic concentrations of 
GCV suggested that the initial drug-induced DNA damage was repaired, consistent with 
our finding that the cells completed progression through the cell cycle,(5) but the 
secondary onset of damage was not repaired (Fig. 2.3).  In contrast, damage initiated by 
araT appeared to be repaired prior to drug washout without further evidence of DNA 
damage thereafter.  Because we have previously demonstrated that araT and GCV 
produce S-phase accumulation and a slowing of DNA replication, we wished to 
determine whether HRR,  the primary repair pathway for stalled replication forks and 
DNA DSBs during S-phase(19;20) was utilized to repair the damage.   Following addition 
of GCV or araT, Rad51 positive cells were measured as an indicator of HRR(21)(Fig. 2.6).  
For both drugs, the number of Rad51 foci increased after drug addition and through 12 
hr post drug washout, after which foci decreased but remained elevated for at least 
another 60 hr.  Analysis of the number of foci per cell in positive cells revealed no 
significant difference between GCV and araT (Fig. 2.7).   Thus, both drugs produced a 
similar activation of Rad51. 
With evidence of DNA damage and its repair, we wished to determine the 
pathway responsible initiation of the γ-H2AX response.  Thus, we evaluated the extent 
to which cells utilized the DNA damage response pathways initiated by ATR and/or ATM 
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following GCV or araT exposure.   In response to replication stress, ATR kinase is 
activated, and its activity can be measured by phosphorylation of its downstream target, 
Chk1 on serine 317 (Fig. 2.8).  Western blot analysis revealed that Chk1 phosphorylation 
was most pronounced during incubation with araT, whereas it decreased rapidly 
following drug washout and persisted at low levels at all subsequent time points 
evaluated.  These results are consistent with the strong DNA replication block that 
occurs during araT incubation but is relieved following drug washout(5). GCV also 
induced an increase in Chk1 phosphorylation that was apparent both during and after 
drug incubation.  These data indicate that, while both drugs initiated an ATR response, 
araT induced a more transient effect. 
DNA damaging agents that produce DNA double strand breaks (DSBs) result in 
activation of ATM kinase, which can be detected by autophosphorylation at S1982 (Fig. 
2.9).  In response to araT (IC90), there was less than a 6-fold increase in ATM 
phosphorylation which persisted throughout the time course evaluated.  When GCV 
(IC90) was added to cells, there was minimal activation of ATM during drug incubation.   
At 24 hr following drug washout, there was a dramatic increase in ATM phosphorylation, 
achieving an increase of nearly 20-fold by 72 hr post washout compared to control, 
indicating a strong DSB response.  Together with the γ-H2AX data, ATM phosphorylation 
identifies the late-occurring DNA damage with GCV as DSBs, whereas cytotoxicity with 
araT is not due to a strong DSB response. 
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Discussion 
Most nucleoside analogues elicit cytotoxicity through incorporation into DNA(22-24).  
However, the extent and mechanism of cell killing can differ between these drugs even 
though their primary event leading to cytotoxicity is similar.  We have demonstrated 
previously that GCV was more cytotoxic than araT, despite the fact that U251 cells 
incorporated at least 5-fold more araTMP than GCVMP into DNA, suggesting that the 
functional consequences of incorporation induced by these nucleoside analogues are 
different(5).  Here we have compared the extent and kinetics of DNA damage induced 
by exposure of tumor cells to GCV or araT, as well as the DNA damage response 
pathways utilized by these drugs.  The results demonstrated that GCV induced 
significantly more DNA DSBs than araT at similarly cytotoxic concentrations as measured 
by γ-H2AX and ATM phosphorylation.  The biphasic kinetics of DNA damage observed 
uniquely with GCV reflected the role of HRR in a failed attempt at DNA repair, leading to 
multi-log cytotoxicity.  Taken together, these data support a distinct mechanism for cell 
death with GCV compared to araT. 
Previous studies have demonstrated that treatment of cells with ionizing radiation or 
cytotoxic drugs induces γ-H2AX foci formation in a dose-dependent fashion(17;25-27).  
In the data presented here, we have used two different methods to demonstrate that 
induction of γ-H2AX increased in a dose-dependent manner with GCV.  Following drug 
washout, the number of γ-H2AX foci decreased demonstrating that the cells were able 
to repair a portion of this damage.  Time dependent resolution of foci formation has 
been demonstrated by others using ionizing radiation(15;25).  The results presented 
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here differ in that we also observed an increase in γ-H2AX foci more than 24 hr after 
GCV washout, which to our knowledge has not been reported previously with other 
DNA damaging agents.  This late increase in foci occurred only at the two cytotoxic 
concentrations of GCV (IC50 and IC90), suggesting that this represents the lethal insult.  
Although the number of foci after GCV washout did not reach as high a level as 
observed during drug incubation, loss of cells due to cell death at this point interfered 
with our ability to quantify foci.  Co-staining for γ-H2AX and BrdUrd demonstrated that 
most of the γ-H2AX foci were in S-phase cells, consistent with our previous data 
demonstrating an S-phase arrest at the times corresponding to the second increase in γ-
H2AX foci.  Association of the late increase in γ-H2AX foci at 48 hr after drug washout 
with cells in S-phase following induction of HRR suggests that the lethal insult occurred 
during attempted replication or repair of DNA.  While many studies have focused on 
determining DNA damage during drug incubation, the studies presented here indicate 
that the critical events leading to cell death may occur long after drug washout. 
Following exposure of cells to araT, γ-H2AX foci formation was strikingly 
different from that observed with GCV.  While there was a dose-dependent increase in 
foci formation with araT, the maximum number of foci was at least 7-fold lower with 
araT despite the fact that more araTMP was incorporated into DNA(5).  This 
demonstrates that it is not simply the absolute amount of nucleotide analog 
incorporated into DNA but the consequences of that incorporation that is important for 
cytotoxicity.  Furthermore, only GCV produced a second increase in γ-H2AX following 
drug washout that was coincident with cell death, demonstrating a role for late DNA 
83
damage in cytotoxicity.  We have reported previously that apoptosis was induced 
similarly with both drugs, thus the increase in γ-H2AX foci following GCV treatment 
cannot be attributed to apoptosis(5).  These findings and the fact that the γ-H2AX 
produced by araT was similar to that observed with a non-cytotoxic concentration of 
GCV implicates a different mechanism of cell death for araT vs. GCV. 
Previous reports demonstrate that GCV induces sister chromatid exchanges, 
suggesting a role for HRR in responding to GCV-induced DNA damage(9;10).  We 
investigated a role for HRR by analyzing Rad51 foci formation following treatment with 
GCV and araT.   The results demonstrated that HRR was induced only after drug 
washout for both drugs.  Because HRR responds to both stalled replication forks as well 
as DSBs, we further analyzed the DNA damage response pathways initiated by GCV and 
araT.  The results demonstrated that both drugs activated ATR and ATM, though with 
strikingly different kinetics.  The activation of ATR primarily during araT exposure 
indicated greater replicational stress induced by this drug, consistent with the greater 
inhibition of DNA synthesis by araT(5).  The low activation of ATM during and after araT 
exposure suggests that this pathway was used to restart stalled replication forks.  In 
contrast, GCV induced modest activation of ATR during and after drug exposure, 
consistent with its more moderate effect on DNA replication.  GCV induced activation of 
ATM only after drug washout, as HRR declined.  The concurrent increase in ATM 
activation and γ-H2AX foci after GCV indicates that the foci represent DSBs, consistent 
with reports by others of GCV-induced DSBs in other cell types(8).  A recent report also 
observed an increase in Chk1 phosphorylation, a late increase in activation of a 
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downstream ATM substrate, Chk2, and an increase in γ-H2AX foci at a single late time 
point after addition of GCV and an adenovirus that transiently expressed HSV-TK(28).  
However, these studies evaluated only a single, high concentration of GCV with variable 
amounts of adenovirus for transduction.  Furthermore, they did not report controls for 
the effect of the adenovirus alone and thus the relative contribution of adenovirus 
transduction vs. GCV to the checkpoint alterations cannot be determined. 
Based on our findings, we propose the following model for GCV cytotoxicity: 
During the first cell cycle, GCVMP incorporation into DNA slows DNA replication 
resulting in activation of ATR/Chk1 and a subsequent increase in γ-H2AX foci formation 
as the cell attempts to replicate past or correct this lesion.  Completion of DNA 
replication, as evidenced by progression through the cell cycle, allows γ-H2AX foci to 
resolve.  During the next entry into S-phase, GCVMP in the DNA template either doesn’t 
serve as a good substrate for replication, or it is recognized as fraudulent and the cell 
attempts to repair it.   DNA replication is halted and HRR is used in an attempt to restart 
replication and/or repair the lesion as evidenced by an increase in Rad51.  However, 
GCVMP blocks HRR from successfully completing repair, and strong activation of ATM 
concurrent with γ-H2AX foci indicates formation of DSBs that prevent completion of S-
phase resulting in massive cell death.  In contrast, araT produced a strong activation of 
ATR during drug incubation and a modest increase in ATR and ATM activation in the 
absence of γ-H2AX foci after drug washout, consistent with successful restarting of 
stalled replication forks.   These data indicate that araTMP in DNA can stall replication 
but the cell can successfully resume synthesis.  In contrast, GCVMP is accommodated 
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more readily in the nascent DNA, but it will not support replication when present in the 
DNA template. 
In summary, the data demonstrate that the inability of HRR to repair GCV-
mediated damage produced DSBs that resulted in cell death with GCV, whereas the 
mechanism of cell death with araT was distinctly different.  Furthermore, at similarly 
cytotoxic concentrations DNA damage was less severe with araT and did not persist, 
whereas GCV induced greater DNA damage and it occurred in biphasic fashion.  We 
suggest that GCVMP in the template blocked successful repair by HRR, leading to cell 
death.  In contrast, we suggest that most of the DNA damage induced by araT was 
repaired, and cell effects other than direct DNA damage, such as signaling to cell death 
pathways,(29) results in cytotoxicity.  These studies highlight that a novel mechanism 
accounts for the impressive antitumor activity of HSV-TK/GCV suicide gene therapy.  
These findings suggest that combining HSV-TK/GCV with approaches that compromise 
HRR will produce synergistic antitumor effects. 
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% BrdUrd  
Positive   
% γ-H2AX 
 Positive 
% of γ-H2AX Positive 
that are  also 
BrdUrd Positive 
   C  46  + 9  26 + 16 67 + 31 
0 hr  IC10  57 + 6 59 + 20 64 + 17 
   IC50  65 + 6 80 + 16 79 + 12 
   IC90  85 + 21 95 + 3 86 + 19 
      
   C  38 15 75 
24 hr  IC10  77 + 28 11 + 4 25 + 35 
   IC50  63 + 5 20 + 3 41 + 8 
   IC90  56 + 62 72 + 22 57 + 61 
      
   C  n.d.  n.d.  n.d.  
48 hr  IC10  38 + 3 8 + 5 70 + 42 
   IC50  62 + 8 72 + 21 79 + 14 
   IC90  0 90 0  
Table 2.1. Colocalization of γ-H2AX and BrdUrd in response to GCV. U251tk  
cells were incubated with GCV at the indicated concentrations (IC10 = 0.03 mM,  
IC50=0.05 mM, IC90=0.2 mM) for 24 h followed by drug washout.  Cells were  
assayed for γ-H2AX foci formation and bromodeoxyuridine (BrdUrd) staining at  
The indicated time points.  Time = 0 represents the time of drug washout.   
Values represent the percentage of cells that stained positive for γ-H2AX  
(contained greater than 5 foci), BrdUrd, or both.  At least 50 cells were counted 
 at each time point.  n.d.= not determined. 
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Figure 2.1 GCV induces a dose-dependent increase in γ-H2AX. U251tk cells  
were incubated with GCV for 24 hr and assayed for γ-H2AX foci formation.   
(A) representative cells as captured by confocal microscopy; (B) quantitation  
of the number γ-H2AX foci per cell.  Points represent mean of triplicate  
experiments; bars represent standard error. 
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Figure 2.2 GCV induces a dose-dependent increase in γ-H2AX expression.  
U251tk cells were incubated with GCV for 24 hr and assayed for γ-H2AX  
expression by flow cytometry; (A) measurement of γ-H2AX expression by flow  
cytometry after a 24 hr incubation with 1µM GCV (B) quantitation of  
percentage of γ-H2AX expressing cells from flow cytometry. Points represent  
mean of triplicate experiments; bars represent standard error. 
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Figure 2.3 Time course of g-H2AX foci formation in response to GCV. U251tk 
cells  were incubated with GCV at the IC10, IC50 or IC90 for 24 h followed by drug 
washout.  Cells were assayed by confocal microscopy for γ-H2AX foci formation  
at the indicated time points.  Black bar indicates duration of drug incubation,  
points represent the mean of at least three experiments, bars represent standard  
error. 
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Figure 2.4 araT induces a dose-dependent increase in γ-H2AX. U251tk cells 
were incubated with araT for 24 hr and assayed for γ-H2AX foci formation. (A)  
representative cells as captured by confocal microscopy; (B) quantitation of  
the number γ-H2AX foci per cell. Columns, average of at least three separate  
experiments; bars, SE. 
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Figure 2.5 Time course of γ-H2AX foci formation in response to araT. U251tk cells 
were incubated with 100mM araT (IC80) for 24 hr followed by drug washout. Cells 
were assayed for γ-H2AX foci formation by confocal microscopy at the indicated time 
points and the number of γ-H2AX foci per cell was determined. Black bar indicates 
duration of drug incubation. Points, mean of at least three experiments; bars, 
standard error. 
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Figure 2.6 Time course of Rad51 foci formation in response to GCV or araT.  
U251tk cells were incubated with (▲) IC90 GCV or (■) IC80 araT for 24 h 
followed by drug washout. Cells were assayed by confocal microscopy for 
Rad51 at the indicated time points (positive cell = >10 Rad51 foci).  Black bar 
indicates duration of drug incubation, points represent the mean of at least 
three wells from a representative experiment, bars represent standard error. 
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Figure. 2.7 Rad51 foci number in Rad51 positive cells in response to GCV or araT.  
U251tk cells were incubated with IC90 GCV or IC80 araT for 24 h followed by drug 
washout. Cells were assayed by confocal microscopy for Rad51 at the indicated 
time points (positive cell = >10 Rad51 foci).  Data represents the average foci per 
cell in positive cells only.  Black bar indicates duration of drug incubation, bars 
represent the mean of at least three wells from a representative experiment, error 
bars represent standard error. 
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Figure 2.8 Time course of Chk1 phosphorylation in response to GCV or araT.  
U251tk cells were incubated with (A) IC90 GCV or (B) IC90 araT for 24h followed by 
drug  washout.  pChk1(Ser317) was assayed by western blot at the indicated time 
points.  Total Chk1 and actin were used as loading controls. 
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Figure 2.9 Time course of ATM activation in response to GCV or araT.  
U251tk cells were incubated with (A) IC90 GCV or (B) IC90 araT for 24h 
followed by drug washout.  pATM (Ser1982) was assayed by western blot at 
the indicated time points.  Total ATM was used as a loading control. 
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Chapter III 
Vorinostat Synergistically Enhances HSV-TK/Ganciclovir Gene Therapy by Inhibiting 
Homologous Recombination 
 
 
Summary 
Many chemotherapeutic agents target DNA synthesis by either inhibiting DNA 
precursors or by direct incorporation into DNA.  Among these compounds are 
nucleoside analogs, which resemble endogenous DNA substrates and can compete for 
incorporation into DNA resulting in the inhibition of DNA synthesis.  In response to this 
inhibition, cells activate DNA repair mechanisms in order to complete DNA replication.  
However, the choice of DNA repair pathway, extent of repair activation, and the amount 
of cell kill can vary between different nucleoside analogs.  Previous studies evaluating 
antiviral nucleoside analogs in a suicide gene (herpes simplex virus thymidine kinase) 
therapy approach to cancer treatment demonstrated that ganciclovir (GCV) 
incorporation into DNA causes a unique cellular response and elicits superior tumor cell 
killing compared to other nucleoside analogs used in the same gene therapy setting.  
Recently, we explored the mechanism by which GCV elicits superior cytotoxicity and 
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demonstrated a potential role for the DNA repair pathway of homologous 
recombination (HR) in response to GCV.   Here, we extended these studies by evaluating 
GCV sensitivity in isogenic cell lines either proficient or deficient in HR.  The results 
demonstrate that HR promotes survival in response to GCV.  Based on this observation, 
we hypothesized that pharmacologic inhibition of HR will result in synergistic cell kill 
when combined with GCV.  In light of previous reports demonstrating that inhibition of 
lysine deacetylases (KDACs) can inhibit HR, we evaluated the ability of suberoylanilide 
hydroxamic acid (SAHA; Vorinostat) to inhibit HR and enhance GCV cytotoxicity.  In a cell 
based recombination reporter assay, SAHA (1 to 10µM) produced increasing inhibition 
(51 to 85%) of HR.  Western blot analysis demonstrated a concentration-dependent 
decrease in the HR specific protein Rad51.  At concentrations of SAHA that inhibited HR 
and decreased Rad51 expression, Rad51 foci formation was completely blocked with 
GCV treatment.  SAHA also produced synergistic cytotoxicity in combination with GCV in 
HR proficient cells but only additive cell kill in HR deficient cells.  Collectively, these data 
demonstrate that HR promotes survival in response to GCV and inhibition of this repair 
by SAHA results in synergistic cell kill.  These studies suggest that inhibiting DNA repair 
prior to targeted DNA damaging approaches, such as suicide gene therapy, will provide 
a selective method for improving cancer therapy.   
 
Introduction 
Many nucleoside analogs inhibit DNA synthesis making them useful in the 
treatment of viral infections and certain cancers.  In the context of cancer treatment, 
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the cellular responses, tumor cell kill, and patient toxicity varies depending the 
nucleoside analog used.  Therefore a greater understanding of the mechanism of action 
of nucleoside analogs is required in order to rationally predict which nucleoside analog 
will be most beneficial to patients and identify the pathways for triggering cell death in 
tumor cells.   
Ganciclovir (GCV) is an antiviral nucleoside analog used in suicide gene therapy 
approaches for the treatment of cancer.  In order to be cytotoxic, GCV must be activated 
to its triphosphate, requiring herpes simplex virus thymidine kinase (HSV-TK) for the 
initial phosphorylation because mammalian kinases cannot use GCV as a substrate.  
Gene therapy approaches exploit this selectivity by delivering the HSV-TK cDNA as a 
“suicide gene” only to tumor cells followed by treatment with the substrate ganciclovir 
(GCV).  With this strategy, only the cells containing the suicide gene are capable of 
activating a prodrug to a toxic metabolite, thus conferring selectivity for tumor cells 
while sparing normal dividing tissues.  This therapy has demonstrated exquisite 
selectivity and excellent antitumor activity in many preclinical models which has 
resulted in several clinical trials including a combination approach in patients with 
prostate cancer(1-5).   
Previous studies have demonstrated that GCV is more cytotoxic than other HSV-
TK substrates such as 1-β-D-arabinofuranosylthymine (araT) despite the fact that GCV 
becomes incorporated into DNA to a lesser extent than araT(6), suggesting GCV has a 
unique mechanism of cell killing.  Furthermore, at subcytotoxic concentrations, GCV 
induces sister chromatid exchanges (SCEs) whereas other HSV-TK substrates did not(7) 
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suggesting a potential role for the DNA repair pathway of homologous recombination 
(HR) in response to GCV.  However, at cytotoxic concentrations SCEs were not observed 
potentially due to increased DNA synthesis inhibition by GCV(7).  Using Rad51 foci as a 
direct indicator of HR events, we demonstrated a role for HR in response to GCV at 
cytotoxic concentrations(8).  Although these studies demonstrate that HR is activated in 
response to GCV, they do not address the exact role of HR in promoting either cell 
survival or cell death.  To address this question, O’Konek et al demonstrated that yeast 
strains deficient in HR are more sensitive to GCV than the corresponding WT strains(9).  
However, HR has a greater role in DNA repair in yeast compared to mammalian 
cells(10;11) therefore whether or not mammalian cells also utilize HR to survive GCV 
exposure is yet to be addressed.   
Based on the observation that HR promotes cell survival in response to GCV in 
yeast, we hypothesized that HR promotes cellular survival in mammalian cells as well.  
Furthermore, we hypothesized that pharmacological inhibition of HR would result in 
synergistic tumor cell kill with GCV in HSV-TK expressing cells.  While there are currently 
no inhibitors specifically for HR, Buggey et al demonstrated that the KDAC inhibitor PCI-
24781 decreased the number of HR events in a cell based assay, abolished ionizing 
radiation (IR) induced Rad51 foci formation and decreased the expression of several 
proteins required for HR including Rad51(12).  Furthermore it has been demonstrated 
that inhibition of KDAC enzymes results in persistent γH2AX and 53BP1 foci after IR(13), 
which accumulate at sites of DNA damage and recruit downstream repair proteins.   
Finally, KDAC inhibitors have recently been demonstrated to have excellent antitumor 
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activity when combined with DNA damaging agents prompting numerous clinical 
trials(14-19).   
In addition to the potential increased GCV mediated cytotoxicity due to 
inhibition of HR, recent reports evaluating GCV in combination with the KDAC inhibitors 
noted improvements in suicide gene delivery and expression making these drugs an 
attractive combination with HSV-TK/GCV gene therapy(20;21).  However, the role of HR 
repair in response to GCV in mammalian cells was previously unknown and therefore 
not considered in combination therapy strategies.    Here, we demonstrate that HR 
promotes survival in response to GCV in mammalian cells providing another potential 
mechanism to be exploited pharmacologically to enhance GCV mediated cell kill.  For 
our studies we evaluated the combination of the KDAC inhibitor Vorinostat (SAHA) with 
GCV in HSV-TK expressing cells because SAHA selectively affects cancer cells compared 
to normal non-transformed cells(22).  The results demonstrate that SAHA inhibits HR 
and blocks HR repair of GCV induced DNA damage.  Importantly, GCV and SAHA 
synergize only in HR proficient cells suggesting the synergy observed with GCV and SAHA 
is specifically due to inhibition of HR by SAHA.   
 
Material and methods 
Cell Culture 
U251 human glioblastoma cells were maintained in RPMI 1640 medium supplemented 
with 10% calf serum (GIBCO, Grand Island, NY) and L-glutamine (Fisher Scientific, 
Pittsburgh, PA).  Cells were maintained in exponential growth in a humidified 
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atmosphere at 37ºC and 5% CO2.   U251 cells stably expressing HSV-TK were generated 
as previously described(6).  AA8 and irs1SF CHO cell lines were maintained in MEMα 
supplemented with 10% FBS (Gibco) and L-glutamine (Fisher Scientific) and maintained 
as described above.  AA8 and irs1SF clonal cell lines were developed from parental cells 
using a retrovirus vector containing the cDNA for HSV-TK and LacZ(23).  cDNAs were 
inserted into the pLKO.1-puro plasmid using EcoRI and BamHI.  HeLa cells containing the 
DR-GFP construct (donated by Dr. Jasin) were maintained in DMEM containing 10% FBS 
and L-Glutamine were generated as previously described and maintained as described 
above.  Individual clones expressing HSV-TK were generated as described above for the 
U251tk cell lines. 
 
Western blots and immunohistochemistry: 
Western blots were done according to standard protocol.  Primary antibodies used were 
as follows: Rad51 (calbiochem), actin (calbiochem), histone 3, histone 3 acetyl-lysine 9, 
CtIP (cell signaling), HSV-TK (produced and donated by Dr. Black(24)).  Rad51 foci 
formation was performed as previously described(8).  Images of representative cell 
populations were captured, and Rad51 positive cells were scored visually (cells with 10+ 
foci were considered positive).  For evaluating RPA (Lab Vision/NeoMarkers) foci 
formation after IR, U251tk cells were seeded on chambered slides.  After 48hr, the 
indicated concentrations of GCV were added for 24hr followed by drug washout.  24hr 
after GCV washout cells were treated with 10Gy IR.  1hr post IR cells were fixed and 
stained for RPA and γ-H2AX (Trevagen).  RPA and γ-H2AX staining was performed using 
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the same protocols as those used for evaluating Rad51 foci formation.  Primary 
antibodies were mouse anti-RPA p34 (Lab Vision/NeoMarkers) and rabbit anti-γ-H2AX 
(Trevigen).  Secondary antibodies were AlexaFluor 594-conjugated goat anti-mouse and 
AlexaFluor 488-conjugated goat anti-rabbit (each at 1:1000 dilution, Molecular Probes) 
for RPA and γ-H2AX, respectively.   
 
Analysis of GCV metabolism and incorporation 
Analysis of cellular deoxynucleotide triphosphates, GCV metabolism, and GCV 
incorporation was performed as previously described(6) with the following exceptions: 
Experiments measuring cellular deoxynucleotide triphosphates in U251tk cells were 
performed in cells treated with IC90 GCV (0.1µM) GCV for either 8 or 24hr.  In AA8tk and 
irs1SFtk cells, IC90 (2µM or 0.2µM, respectively) for 8 or 16hr was used.  Experiments 
measuring GCVTP and incorporation into DNA in U251tk cells were perfomed in cells 
treated with IC90 (0.1µM) [3H]GCV (Moravek Biochemicals, Inc., Brea, CA) for either 8 or 
24hr.  In AA8tk and irs1SFtk cells, each cell line was treated with 2µM or 0.2µM GCV (5% 
or 50% [3H]GCV, respectively) for 8 or 16hr.   
 
Analysis of cell cycle 
U251 cells expressing HSV-TK were grown in T25 flasks for 48hr prior to drug treatment.  
Cells were treated with GCV and/or SAHA at the indicated concentrations.  All drug 
incubations were for 24hr unless otherwise noted.  At the indicated times, cells were 
trypsinized and prepared for flow cytometry as previously described(6).   Analysis was 
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performed on BD FacsCalibur at the University of Michigan Flow Cytometry Core Facility.  
At least 10,000 cells were evaluated for each condition, and the experiment was 
performed at least two times. Cell cycle phase was analyzed by Mod-fit LT (version 
3.3.11, Verity Software House, Topsham, ME)  
 
Clonogenic cell survival assay, isobologram analysis, and measurement of HR (DR-GFP 
assay) 
Clonogenic cell survival assays were performed as previously described(1) with the 
exception that the AA8, AA8tk, irs1SF, and irs1SFtk cell lines were incubated in GCV 
and/or SAHA for 16hr.  Isobologram analysis was applied to these dose-response curves 
as previously described(25).  Each experiment was performed at least two times in 
triplicate.  HeLa-DR-GFPtk cells were plated on 6-well plates at 1e5 cells/well.  48hr 
later, the indicated concentration of SAHA and/or adenovirus containing the ISceI cDNA 
was administered for 24hr.  At the end of drug/virus incubation, fresh media was 
supplemented for 24hr.  Cells were then trypsinized (0.25% trypsin, (Gibco)) for 5 min, 
pelleted by centrifugation (1000g for 5min), and resuspended in 0.5ml 1% formaldehyde 
(Fisher Scientific).  Cells were analyzed for GFP expression by flow cytometry as 
described above.  Data was analyzed using WinMDI software (version 2.9).  Graph 
represents 3 individual experiments performed in triplicate.  
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Results 
Homologous Recombination Promotes Survival in Response to Ganciclovir 
Previously, we demonstrated a role for HR in response to GCV in mammalian 
cells(8) and that HR promotes survival in response to GCV in yeast(9).  To determine the 
role of HR in response to GCV in mammalian cells, we evaluated GCV cytotoxicity in CHO 
cell lines either proficient (AA8) or deficient in HR (irs1SF) cell lines.  Individual clones of 
each cell line stably expressing HSV-TK were generated using a retroviral vector.  Cell 
lines stably expressing Lac-Z were used as controls for viral transduction.  Using two 
separate clones of both HR proficient and deficient cell lines, the results demonstrated 
that HR-deficient irs1SFtk cells were >14-fold more sensitive (p = 0.013) to GCV than HR-
proficient AA8tk cells indicating that HR promotes survival in response to GCV (IC50 = 
0.08 + 0.011 µM vs. 1.14 + 0.694 µM, respectively)(Fig. 3.1).  Importantly, the HR-
deficient cells were more sensitive despite the fact that the AA8tk clones expressed 
similar levels of HSV-TK (Fig. 3.2) and accumulated similar levels of the active metabolite 
GCVTP after 8hr of [3H]GCV incubation (3.15 + 0.07 and 2.96 + 0.07 nMoles/10e7 cells 
after 0.2µM (p = 0.8515) and 27.91 + 6.64 vs. 33.95 + 3.26 nMoles/10e7 cells after 2µM 
(p = 0.4596) AA8tk6 and irs1SFtk22, respectively)(Fig. 3.4).   Furthermore, dGTP, the 
endogenous competitor of GCVTP for incorporation into DNA, did not change 
significantly in response to GCV treatment in either cell line (Fig. 3.3).  Finally, AA8tk 
cells incorporated as much or more GCV monophosphate (GCVMP) into DNA than 
irs1SFtk cells (2.84 fold + 0.11 at 0.2µM (p < 0.0001) and 1.38 + 0.41 at 2µM (p = 0.0853) 
after 8hr and 2.10 + 0.18 at 0.2µM (p = 0.0053) and 2.31 + 0.05 at 2µM (p < 0.0001) 
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after 16hr, respectively)(Fig. 3.5).  Collectively, these data demonstrate that altered 
metabolism of GCV, decreased dGTP, or GCVMP incorporation into DNA cannot explain 
the differences in cytotoxicity observed between the cell lines.   Thus, HR promotes 
survival in the AA8tk cells.    
 With the compelling data implicating a strong role for HR in promoting survival 
in the CHO cell lines, we wished to evaluate a role for HR in promoting survival with GCV 
in matched human cell lines with and without HR, utilizing shRNA mediated depletion of 
the HR required proteins Rad51 and XRCC3.  Depletion of either Rad51 or XRCC3 in 
U251tk cell lines was toxic to the cells, thus sensitivity to GCV could not be measured 
(data not shown).  To circumvent the toxicity associated with shRNA depletion of HR 
required proteins, we attempted to overexpress the HR required proteins Rad51, CtIP, 
and/or Exo1.  Similar to what was observed with depletion of HR required proteins, 
overexpressing HR proteins also proved to be toxic (data not shown).  Furthermore, we 
were not able to obtain cells with sustained overexpression of CtIP and/or Rad51 
despite puromycin selection for the shRNA-transduced cells (data not shown) suggesting 
overexpression of HR required proteins confers a disadvantage for cellular proliferation 
resulting in selection of cells with normal expression of the HR required protein.   
 
Cell cycle in AA8tk and irs1SFtk cells in response to GCV 
To determine if HR deficiency resulted in altered cell cycle effects in response to 
GCV, cell growth and dual parameter cell cycle analysis was performed in both HR 
proficient and deficient cell lines.  Similar to previous observations in human cell lines, 
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growth of AA8tk cells treated with IC90 GCV was inhibited until approximately 24hr after 
GCV removal when cell number decreased due to cell death (Fig. 3.6).  Cell cycle analysis 
demonstrated an increase in early S-phase cells 4hr into GCV incubation (Fig. 3.7).  As 
time progressed, the number of cells in mid S, late S, and G1 increased suggesting cells 
were progressing through the cell cycle.  Upon entry into the second cell cycle, cells 
arrested in S and G2/M suggesting permanent arrest in the second cell cycle until cell 
death occurred.  Conversely in the HR deficient irs1SFtk cell line, cell growth (Fig. 3.6) 
and cell cycle analysis (Fig. 3.8) demonstrated that treatment with IC90 GCV resulted in 
no cell cycle or growth perturbation, which was verified using a second, independent 
irs1SFtk clone (data not shown).  The HR deficiency in the irs1SF cell line is due to the 
lack of the HR required protein XRCC3.  To determine whether the lack of cell cycle 
perturbation in response to GCV was the result of XRCC3 depletion or specific to the 
irs1SF cell line, cell cycle analysis after incubation with GCV was evaluated in human 
U251tk glioblastoma cells after shRNA of XRCC3 (Fig. 3.9, 3.10).  Depletion of XRCC3 
alone was toxic to cells in the colony formation assay performed to measure changes in 
GCV sensitivity, however this assay requires trypsinizing and replating of cells at low 
density.  If cells are not trypsinized, they continued to grow until confluence suggesting 
alterations in cell cycle could be measured after depletion of XRCC3.  A non-specific 
shRNA was used to control for viral infection.  In control cells and non-specific shRNA 
treated cells, the cell cycle of U251tk cells is moderately inhibited during GCV treatment 
and permanent arrest occurs 24hr after removal of GCV.  In XRCC3 depleted cells there 
was no cell cycle perturbation until 48hr post GCV washout.  At 48hr, cells arrested in S 
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and G2/M of the cell cycle.  Based on previous experiments with retroviral delivery of 
shRNAs to deplete proteins, the expression of XRCC3 may be restored 48hr after GCV 
removal (data not shown).  These data suggest that HR is responding to GCVMP in 
template DNA in an XRCC3 dependent manner to prevent or repair lesions that will later 
result in cell death, however at cytotoxic concentrations HR fails to repair GCV induced 
DNA damage resulting in cell death.   
 
DNA resection in the presence of GCVMP in template DNA 
After treatment with GCV, we hypothesized that GCVMP in the template strand 
of DNA induces double strand breaks during replication(8).  We further hypothesize that 
cells attempt to repair GCV induced DNA damage with HR, which involves DNA resection 
of the GCVMP containing template strand.  Resection of GCVMP from DNA provides the 
only step in the repair pathway in which repair enzymes must chemically react with the 
modified carbohydrate moiety of GCVMP.  Furthermore, previous studies have 
demonstrated that GCVMP remains incorporated in DNA for at least 96hr after 
removing GCV(6).  Therefore, we hypothesize that GCV can inhibit DNA resection.  To 
address this hypothesis we attempted to evaluate the ability of GCVMP in DNA to inhibit 
DNA resection during HR after IR.  Previous reports have demonstrated that depletion of 
the HR required exonuclease CtIP prevents focal accumulation of RPA(26), a protein that 
coats single stranded DNA generated by resection, indicating resection does not occur in 
the absence of CtIP(26).  In light of these findings, we attempted to evaluate RPA foci 
formation in cells pretreated with GCV and treated with IR, which induces DNA double 
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strand breaks, many of which are repaired by HR during S phase thus DNA must be 
resected in order for HR to occur(26)(Fig. 3.11, 3.12).  To increase the probability of an 
IR induced DSB occurring in proximity of incorporated GCVMP, high concentrations of 
GCV and IR were used.  The results demonstrated that after 10Gy IR, a decrease in the 
average RPA foci per cell from 44.3 + 12.2 to 25.9 + 4.6 and 16.5 + 4.2 if cells were 
pretreated with 0.1µM (IC90) or 1µM (IC99) GCV, respectively.  However, at 10µM we 
observed an increase in the average RPA foci per cell and variability between cells (61.2 
+ 36.4) indicating that RPA foci formation after IR in cells pretreated with GCV may not 
be an adequate method for measuring resection through GCVMP-containing DNA during 
HR. 
GCV inhibits HR 
Results from the studies in the HR proficient and deficient CHO cell lines 
demonstrate that HR promotes survival in response to GCV, however, at cytotoxic 
concentrations HR fails to save the cell and cell death occurs.  To determine whether 
GCV directly inhibits HR we measured HR events in a previously described cell based  
(DR-GFP) reporter assay(27) in the presence or absence of GCV.  Briefly, a double strand 
break is enzymatically induced in a nonfunctional GFP (Fig. 3.14).  If repaired by HR, a 
functional, nonexpressed GFP will be used to resynthesize the damaged area resulting in 
a functional GFP gene.  The expression of GFP can be detected subsequently by flow 
cytometry.  Using HeLa cells, we generated monoclonal populations of cells containing 
the DR-GFP reporter construct that also stably express HSV-TK (Fig. 3.13).  Monoclonal 
cell lines were isolated and GCV sensitivity was assessed (Fig. 3.13).  Hela-DR-GFPtk 
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clone 6 was used for HR studies.  Using an adenovirus containing the cDNA for the I-SceI 
endonuclease, a DSB was generated and HR events were monitored by flow cytometery 
at the indicated concentrations of GCV (Fig. 3.15).  The results demonstrated that GCV 
alone did not significantly increase the percentage of GFP positive cells in the absence of 
the I-SceI endonuclease.  After induction of a double strand break with an adenovirally 
delivered I-SceI endonuclease, a concentration dependent decease in GFP positive cells 
was observed (Fig. 3.15) decreasing from 14.6% + 0.26% in controls to 3.7% + 0.18% 
with 10µM GCV (p<0.0001).  The inhibition of HR required high concentrations of GCV, 
however this is likely attributed to low a frequency of GCVMP incorporation within the 
integrated reporter. Collectively, these data suggest that GCVMP in DNA can inhibit HR 
in this cell based assay.   
 
Synergistic tumor cell kill with GCV and SAHA 
Due to the increased sensitivity to GCV in HR deficient cells, we hypothesized 
that inhibition of HR would enhance cytotoxicity with GCV in HR-proficient cells resulting 
in synergy.  KDAC inhibitors have recently been reported to inhibit HR(12;28), thus we 
evaluated the combination of GCV and the KDAC inhibitor SAHA on cellular survival.  We 
chose to evaluate GCV and SAHA in U251tk glioblastoma cells due to the established 
role of HR in response to GCV in this cell line as indicated by the appearance of Rad51 
foci after GCV treatment(8).  To determine the concentrations of GCV and SAHA to 
evaluate drug synergy with we performed clonogenic cell survival assays with GCV and 
SAHA in U251tk cells to determine the IC5 to IC90 concentrations of GCV and SAHA that 
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could then be used for testing synergistic cytotoxicity(Fig. 3.16).  Based on these results, 
we evaluated the effects of GCV and SAHA at concentrations ranging from 0.3µM to 
30µM of SAHA for our studies.  Further, treatment of U251tk cells over this range of 
SAHA concentrations produced a concentration dependent increase in AceH3K9 at 8 hr 
after drug addition (Fig. 3.17).  Next, we evaluated cytotoxicity with the combination of 
GCV and SAHA (Fig. 3.18). For GCV, the IC25, IC50, and IC90 were used.  For SAHA, 0.3, 1, 3, 
and10µM were used.   Isobologram analysis was used to determine the interaction 
between the two drugs, demonstrating that simultaneous addition of GCV and SAHA 
resulted in synergistic cell kill (Fig. 3.19).  
 
 Increased HSV-TK expression and decreased GCV Incorporation with SAHA 
Previously it has been demonstrated that KDAC inhibition can increase mRNA of 
HSV-TK in stably expressing cells(21).  However, the consequences on HSV-TK protein 
levels and GCV metabolism are yet to be determined.  Therefore, we evaluated the 
expression of HSV-TK in U251tk cells stably expressing the enzyme.  After 24hr of 
incubation, western blot analysis demonstrated a 1.5 fold increase in HSV-TK expression 
in response to SAHA alone and a 2.2 fold increase when GCV and SAHA were 
administered concurrently (Fig. 3.20).  Further, we evaluated the effects on the 
phosphorylation and incorporation of [3H]GCV 8hr and 24hr post addition of [3H]GCV 
and SAHA (Fig. 3.21, 3.22, respectfully) and the effects of SAHA on dGTP levels, the 
endogenous competitor to GCV (Fig. 3.23).  The results demonstrated a 2.2 fold 
decrease in the [3H]GCVTP after 8hr of incubation with SAHA and a maximal 1.8 fold 
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increase in amount of [3H]GCVTP after 24hr coincubation with 3µM SAHA.  In addition, 
SAHA does not significantly alter dGTP levels in combination with GCV.  Finally, 
measurement of incorporation of [3H]GCV into DNA revealed that SAHA did not alter 
incorporation after 8 hr, but after 24 hr there was a concentration-dependent decrease 
in incorporation, with a maximal reduction of 12-fold (22.3+ 0.81 to 1.88 + 0.25 
pmol/10e7 cells).  Collectively, these data exclude the possibility that the synergistic 
cytotoxicity observed between GCV and SAHA is due to altered metabolism of 
endogenous nucleotides or GCV in response to SAHA.    
 
Inhibition of HR with SAHA 
Previously, we have demonstrated a role for the DNA damage response in the 
cytotoxicity of GCV(8).  In particular, we demonstrated an increase in foci formation of 
the homologous recombination (HR) specific protein Rad51 during the second cell cycle 
after drug exposure.  The Rad51 foci increase coincides with entry of cells into the 
second S-phase after the addition of GCV at which time cells permanently arrested and 
underwent apoptosis. Using a cell based assay, Buggy, et al demonstrated that the 
HDAC inhibitor PCI-24781 inhibits HR(12).  Therefore, we evaluated the protein levels 
HR required proteins in response to SAHA including Rad51 and CtIP, a required 
exonuclease for DNA resection during HR.  The results demonstrated SAHA alone didn’t 
alter CtIP except at 10µM, whereas GCV produced a strong increase in CtIP that was 
blocked by SAHA in a concentration dependent manner, decreasing to 48%, 31% and 5% 
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of that observed with GCV alone with 1µM, 3µM and 10µM SAHA, respectively (Fig. 
3.24).   
Additionally, the results demonstrated a concentration dependent decrease in 
Rad51 to 39% of control at 3µM and 8% of control at 20µM of SAHA alone (Fig. 3.25).  
Notably, the combination of SAHA with an IC90 of GCV resulted in a decrease in Rad51 
protein to less than 50% of GCV alone at 1µM SAHA and only 4% remained at the 20µM.  
We also evaluated Rad51 foci formation in response to GCV and SAHA (Fig. 3.26).  The 
results demonstrated that the addition of 1µM SAHA decreased the percent of Rad51 
positive cells with an IC90 of GCV from 16.5 to 0.33 fold increase over control 24hr post 
drug washout.  Strikingly, there were no Rad51 positive cells after treatment and IC90 of 
GCV with 3 or 10µM SAHA or with any concentration of SAHA alone at any of the time 
points evaluated.   Collectively, these results indicate that synergy between GCV and 
SAHA may be due to inhibition of HR by SAHA.    
To further support the hypothesis that SAHA inhibits HR we measured HR events 
in a cell based DR-GFP assay  in the presence or absence of SAHA similar to Fig. 3.15(27).  
The results demonstrated that SAHA reduced HR events in a concentration dependent 
manner with the percentage of GFP positive cells decreasing to 49% +6.1%, 64% +2.4%, 
and 15% + 1.3% of controls at 1µM, 3µM, and 10µM, respectively (Fig. 3.27).  
Importantly, the concentrations used that inhibited HR were only mildly cytotoxic (Fig. 
3.28).  Taken together, with the data demonstrating a decrease in Rad51 protein levels 
and abolishment of GCV induced Rad51 foci, these experiments confirmed that SAHA 
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inhibits HR supporting the hypothesis that SAHA produces synergistic cytotoxicity with 
GCV by inhibiting HR.   
 
Cell cycle effects with GCV and SAHA  
Previously, we reported that GCV causes an arrest in the second S-phase of the 
cell cycle after drug addition(6).  HR is used in S and G2 of the cell cycle, therefore our 
results demonstrating decreased HR events in a cell based assay, decreased Rad51 
expression and lack of Rad51 foci in response to GCV and SAHA could be explained by 
SAHA causing cell cycle arrest in G1 of the second cell cycle after drug addition prior to 
entry into the second S phase where HR would occur.  Therefore, we evaluated the cell 
cycle effects of SAHA alone and with GCV (Fig. 3.29).  The results demonstrated that 
there are at least as many cells in S and G2 with the combination of GCV and SAHA as 
with GCV alone, indicating that the combination does not cause a G1 arrest.  Thus, our 
findings that SAHA decreased Rad51 expression and HR events in a cell based assay 
cannot be explained simply by a G1 arrest.   
 
Synergistic cell kill only in HR proficient cells with GCV and SAHA 
Based on our hypothesis that the synergy of GCV and SAHA is due to inhibition of 
HR, we further hypothesized that the combination of GCV and SAHA would be additive 
or antagonistic in cells lacking HR.  To test this hypothesis, we evaluated the drug 
interaction in HR proficient and deficient CHO cells stably expressing HSV-TK.  Four 
concentrations of both GCV and SAHA were used ranging from subcytotoxic 
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concentrations (<IC5) to ~IC75 for each drug.  The results demonstrated that irs1SFtk cells 
are more sensitive to SAHA as a single agent (data not shown).  Further, using the 
isobologram analysis, we demonstrated that GCV and SAHA synergize in HR proficient 
cells but are only additive in HR deficient cells (Fig. 3.30).   These data support the 
hypothesis that the drug synergy observed with GCV and SAHA is the result of inhibition 
of HR repair in response to GCV induced DNA damage by SAHA. 
 
 
Discussion 
A better understanding of the mechanistic differences in tumor cell killing by 
nucleoside analogs will identify which pathways are important for triggering cell death 
which can be used for future drug targeting strategies.   Suicide gene therapy with HSV-
TK/GCV is a promising approach for treating cancer while minimizing the toxicities 
associated with many traditional chemotherapeutic regimens.  Importantly, GCV has 
superior cytotoxicity in HSV-TK expressing cells compared to other HSV-TK substrates(6) 
and has a unique mechanism of cell killing compared all nucleoside analogs studied to 
date.  Here, we demonstrate that HR promotes survival in response to GCV and identify 
SAHA as an inhibitor of HR that enhances the cytotoxicity of GCV providing a novel drug 
combination for HSV-TK/GCV gene therapy.   
Previous studies have demonstrated that after the addition of GCV to HSV-TK 
expressing cells, moderate DNA synthesis inhibition is observed in the first cell cycle 
followed by S-phase arrest in the second cell cycle(6).  Immunohistochemical studies 
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demonstrated that cell cycle arrest is accompanied by an increase in DNA damage and 
activation of HR(8) which promotes cell survival in yeast(9).  Here, using isogenic cell 
lines either proficient or deficient in HR, we demonstrate that HR promotes survival in 
response to GCV in mammalian cells.  This observation suggests that inhibition of HR will 
result in enhanced GCV cytotoxicity.  Using the KDAC inhibitor SAHA to inhibit HR, we 
demonstrate that GCV and SAHA synergistically kill HR proficient cells.  Collectively, 
these studies provide a mechanistic rationale for evaluating the combination of GCV and 
SAHA in vivo.   
While these studies demonstrate that inhibiting HR enhances the cytotoxicity, a 
better understanding of why HR fails to promote cell survival in response to GCV may 
uncover novel steps within the repair pathway that can be selectively targeted for 
enhancing the efficacy of DNA damaging agents.  The observation that HR promotes 
survival in response to GCV raises the possibility that, at cytotoxic concentrations GCV, 
GCVMP incorporated into DNA inhibits HR resulting in cell death.  In support of this 
hypothesis, we demonstrated that GCV inhibits the repair of a reporter construct by HR 
in a cell based assay.  To address the specific step of HR that is inhibited by GCV, we 
attempted to evaluate whether GCVMP can inhibit the resection of HR resulting in failed 
repair.  We chose to evaluate resection during HR for the following reasons: GCVMP 
causes stalling of DNA synthesis resulting in cell death when in the DNA template and 
when HR is used to restart DNA replication at a stalled replication fork, the template 
strand of DNA is resected.  Therefore, in order for HR to resect the DNA template to 
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restart a stalled replication fork caused GCVMP in the DNA template, GCVMP must be 
resected by the HR machinery.   
We attempted to address DNA resection during HR in human cell lines by 
measuring RPA foci formation after IR.  RPA forms foci on single stranded DNA 
generated during HR and therefore was used in our studies as an indirect measurement 
of DNA resection(26).  Although the results suggest GCV may be inhibiting DNA 
resection during HR, the variability observed in these experiments limited our ability to 
conclude GCV inhibited DNA resection during HR.   
Based on our results in isogenic cell lines either proficient or deficient in HR 
suggesting that HR promotes survival in response to GCV, we hypothesized that 
pharmacologic inhibition of HR would result in synergistic cell kill with GCV.  While there 
are no compounds that selectively inhibit HR, KDAC inhibitors have been demonstrated 
to decrease HR in cell culture and animal models(12).   
Based on this observation, we evaluated the combination of GCV with the KDAC 
inhibitor and demonstrated that SAHA synergizes with GCV in U251tk cells.  In light of 
the known role of HDACs in altering gene transcription and other cellular processes, we 
evaluated several metabolic parameters to determine if altered metabolism of GCV or 
dGTP, which GCV competes with for incorporation into DNA, is altered by SAHA.  In 
these studies, we observed no significant changes that could contribute to the synergy 
observed with GCV and SAHA.  Conversely, we observed that SAHA decreased Rad51 
protein levels in a concentration dependent manner which was observed despite a 
decrease in the percent of G1 cells where Rad51 is not expressed.  Additionally, SAHA 
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treatment completely inhibited Rad51 foci formation in response to GCV and inhibited 
HR in a cell based assay.  Finally, we observed synergistic cell kill in HR proficient cells 
and only additive cell kill in HR deficient cells.  Together, these results indicate that 
synergistic tumor cell kill in HSV-TK expressing cells is due to inhibition of HR by SAHA.   
Collectively, this study identifies a novel drug combination of SAHA with 
HSVTK/GCV gene therapy.  The observation that HR promotes survival in response to 
GCV reveals that inhibiting HR pharmacologically with drugs such as SAHA enhances the 
cytotoxicity of GCV.  In addition to these findings, recent reports evaluating GCV in 
combination with other KDAC inhibitors demonstrated increases the number of tumor 
cells infected by the adenovirus containing the HSV-TK cDNA(20) increased mRNA 
expression of HSV-TK in stably expressing cells(21) and increased the gap junction 
protein connexin 43,  which increased bystander killing by increasing transfer of 
cytotoxic GCV metabolites from HSV-TK expressing cells to neighboring cells(20;21;29).  
In our studies, we also observed increases in HSV-TK, however we also observed a 
concentration dependent decrease in GCVMP incorporation suggesting increasing HSV-
TK cannot explain the observed synergy with GCV and SAHA.  Further, none of these 
studies considered the contribution of enhancing the cytotoxicity of GCVMP after 
incorporation into DNA with KDAC inhibition.     
Together these studies demonstrate that KDAC inhibitors can improve HSV-
TK/GCV gene therapy by multiple mechanisms.  SAHA is an FDA approved KDAC inhibitor 
that is well tolerated in patients, an important aspect when considering the combination 
with a selective treatment such as gene therapy.  Here, we demonstrate that SAHA can 
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improve gene therapy by a previously unappreciated mechanism: enhancing the 
cytotoxicity of GCV by inhibiting HR repair of GCV induced DNA damage.  This 
observation is significant not only for enhancing HSV-TK/GCV gene therapy but 
potentially other targeted therapies such as ionizing radiation.  While future studies 
evaluating the combination of SAHA with HSV-TK/GCV gene therapy in animal models 
are needed to determine if SAHA increases the efficacy of gene therapy sufficiently to 
warrant human trials, these results indicate a promising new direction for HSV-TK/GCV 
suicide gene therapy.   
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irs1SFTK 
HR deficient 
AA8TK 
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irs1SF 
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Figure 3.1 GCV cytotoxicity in HR proficent and deficient CHO cells. Individual  
clones of HR proficient (AA8) and HR deficient (irs1SF) were used to generate  
isogenic cell lines stably expressing HSV-TK or LacZ using a retrovirus.   
Exponentially growing cell lines indicated  (♦AA8,   AA8LacZ, AA8tk6,  
AA8tk14, ◊irs1SF, □irs1SFLacZ, irs1SFtk19, ∇irs1SFtk22) were exposed to  
increasing concentrations of GCV for  16 h.  Survival was determined by  a  
clonogenic cell survival assay and expressed as a fraction of plating efficiency for  
untreated cells.  Points represent the mean of at least three wells from a  
representative experiment, error bars represent standard error. 
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Figure 3.2 HSV-TK expression in HR proficent (AA8) and deficient (irs1SF) 
cells. Indicated cell lines were stably expressing LacZ (controls) or HSV-TK 
were subjected to western blot analysis. Total actin was used as a loading 
control. 
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IC90 GCV 
Figure 3.3 Effects of GCV on endogenous dNTP pools in AA8tk and irs1SFtk 
cells. AA8tk (top) or irs1SFtk (bottom) cells were incubated with  IC90 GCV 
(2µM or 0.2µM, respectively) for 16hr. At the end of drug incubation cells 
were harvested, nucleotides were purified by acid extraction endogenous 
dNTP pools were separated and measured by HPLC.  Columns, mean; bars, SE 
 
IC90 GCV 
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8hr Post Drug Addition 
16hr Post Drug Addition 
Figure 3.4 GCVTP levels in AA8tk and irs1SFtk cells.  AA8tk or irs1SFtk 
cells were incubated with either 0.2µM [3H]GCV (IC90 irs1SFtk) or 2µM 
[3H]GCV (IC90 AA8) for either 8hr (top) or 16hr (bottom).  At the end of 
drug incubation cells were harvested and nucleotides were purified by 
acid extraction.  [3H]GCVTP metabolites were separated by HPLC and 
quantified by scintillation counting.  Columns, mean; bars, SE 
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16hr Post Drug Addition 
8hr Post Drug Addition 
Figure 3.5 GCVMP incorporation into DNA in AA8tk and irs1SFtk cells. 
AA8tk or irs1SFtk cells were incubated with either 0.2µM [3H]GCV  (IC90 
irs1SFtk) or 2µM  [3H]GCV (IC90 AA8) for either 8hr (top) or 16hr (bottom).  
At  the end of drug incubation cells were harvested.  Nucleic acids were 
purified by acid extraction.  DNA was pelleted by centrifugation and 
resuspended.  Incorporated [3H]GCVMP was measured by scintillation 
counting.  Columns, mean; bars, SE 
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Figure 3.6 Growth inhibition in AA8tk and irs1SFtk cells in response to 
GCV.  Cells were incubated with IC90 GCV for 16hr unless otherwise 
indicated. At the indicated time points cells were collected, counted, and 
prepared for dual parameter cell cycle analysis as described in materials 
and methods.  Cell growth of a single reproducible experiment are shown. 
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Figure 3.7 Cell cycle effects in AA8tk cells in response to GCV.  AA8tk cells 
were incubated with IC90 GCV for 16hr unless otherwise indicated. At the 
indicated time points cells were incubated with 30 μM BrdU for 15 min before 
harvest. Cells were then prepared for dual parameter flow cytometry to 
determine BrdU and DNA content as described in Materials and methods. 
Results of a single reproducible experiment are shown 
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Figure 3.8 Cell cycle effects in irs1SFtk cells in response to GCV.  irs1SFtk cells 
were incubated with IC90 GCV for 16hr unless otherwise indicated. At the 
indicated time points cells were incubated with 30 μM BrdU for 15 min before 
harvest. Cells were then prepared for dual parameter flow cytometry to 
determine BrdU and DNA content as described in Materials and methods. 
Results of a single reproducible experiment are shown 
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Figure 3.9 Cell cycle effects of XRCC3 depletion in U251tk cells in response to  
GCV.  XRCC3 was depleted using an shRNA delivered by retrovirus in U251tk  
cells.  Puromycin was used to select for virally infected cells.  Cells were then  
replated and incubated with IC90 GCV for 24hr. At the indicated time points cells  
were incubated with 30 μM BrdU for 15 min before harvest. Cells were then  
prepared for dual parameter flow cytometry to determine BrdU and DNA content  
as described in Materials and methods. Results of a single reproducible  
experiment are shown. 
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Figure 3.10 Cell cycle effects of XRCC3 depletion in U251tk cells in response 
to GCV.  XRCC3 was depleted using an shRNA delivered by retrovirus in 
U251tk cells.  Puromycin was used to select for virally infected cells.  Cells 
were then replated and incubated with IC90 GCV for 24hr. At the indicated 
time points cells were incubated with 30 μM BrdU for 15 min before harvest. 
Cells were then prepared for dual parameter flow cytometry to determine 
BrdU and DNA content as described in Materials and methods. Results of a 
single reproducible experiment are shown.  NS = non-specific shRNA.   
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10Gy IR Alone 
0.1µM GCV for 24hr  
10Gy IR 24hr post GCV 
washout 
RPA – Green, Dapi - Blue  
Figure 3.11 RPA foci formation after IR in cells pretreated with GCV.  
U251tk cells were either untreated (Top) or incubated with GCV 
(bottom) for 24hr followed by drug removal.  24hr post GCV washout 
cells were treated with 10Gy IR and assayed for RPA foci formation.  
Representative cells as captured by confocal microscopy.   
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Group: 
Avg. 
Foci/Cell + 
IR Alone (10Gy) 44.29 12.15 
IR+0.1µM GCV 25.88 4.58 
IR+1µM GCV 16.45 4.18 
IR+10µM GCV 61.21 36.35 
Figure 3.12 RPA foci formation after IR in cells pretreated with GCV. U251tk  
cells were either untreated or incubated with the indicated concentration of  
GCV for 24hr followed by drug removal.  24hr post GCV washout cells were  
treated with 10Gy IR and assayed for RPA foci formation.  Values represent  
mean of a single reproducible experiment; + represent standard deviation. 
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Figure 3.13 Sensitivity of HeLa-D-GFPtk cells to GCV.  Exponentially growing 
HeLa-D-GFP non-HSV-TK-expressing cells (◦) and HeLa-D-GFPtk cells stably 
expressing HSV-TK (♦, ▪, , ) were exposed to increasing concentrations of 
GCV for 24hr.  Clonogenic cell survival was determined and expressed as a 
fraction of plating efficiency for untreated cells. Points represent a mean of 
triplicate samples, bars represent standard error. Cell line HeLa-D-GFP-TK clone 
6 was chosen for use in subsequent experiments.   
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 Figure 3.14 Schematic of HR repair of the D-GFP reporter construct.  A.) 
SceGFP contains an insert encoding the recognition site of the I-SceI 
endonuclease resulting in a non-functional GFP.  The i-GFP lacks a promoter and 
therefore is not expressed.  B.) I-SceI site can be cleaved into a double strand 
break by the I-SceI endonuclease.  C.) If repaired by HR, the i-GFP is used to 
resynthesize the SceGFP.  D.)This deletes the insert resulting in a functional GFP 
which can be detected by flow cytometry 
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Figure 3.15 GCV inhibits HR repair. Hela-D-GFP-TK cells were incubated in the  
indicated concentration of GCV either with or without the AdNGUS24i 
adenovirus containing the cDNA for the I-SceI enzyme.  48hr later, cells were 
collected, fixed and assessed for GFP expression by flow cytometry. Bars 
represent a mean of at least three experiments run in triplicate, error bars 
represent standard error.  
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(A) GCV 
(B) SAHA 
Figure 3.16 Sensitivity of U251tk cells to GCV or SAHA.  Exponentially growing  
U251tk cells were exposed to increasing concentrations of (A) GCV or  (B) SAHA 
for 24hr.  Clonogenic cell survival was determined and expressed as a fraction of 
plating efficiency for untreated cells. Points represent a mean of triplicate 
samples, bars represent standard error.  
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Figure 3.17 Histone 3 lysine 9 acetylation (AceH3K9) in response to SAHA.  
U251tk cells were incubated with the indicated concentration of SAHA for 8hr.   
AceH3K9 was assayed by western blot.  Total H3 was used as a loading control.  
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Figure 3.18 Sensitivity of U251tk cells to GCV and SAHA.  (A,B) Exponentially  
growing U251tk cells were exposed to increasing concentrations of GCV and 
SAHA for 24hr at the indicated concentrations.  Clonogenic cell survival was 
determined and expressed as a fraction of plating efficiency for untreated 
cells. Points represent a mean of triplicate samples, bars represent standard 
error.  
 
(A)  
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Figure 3.19 Isobologram analysis of GCV and SAHA in U251tk cells. Data from 
the clonogenic survival curves in Fig. 3.21 were used to generate isobolograms.  
The concentration of ganciclovir corresponding to IC25, IC50, and IC90 surviving  
fractions were used alone or in combination with 0.3, 1, 3, and 10µM SAHA.   
Fractions portray a representative experiment plated in triplicate.  Diagonal line,  
isoeffective line of additivity. 
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Figure 3.20 HSV-TK expression in response to SAHA. U251tk cells were 
incubated with the indicated concentration of SAHA alone (A) or SAHA 
and IC90 GCV (B) for 24hr.  HSV-TK was assessed by western blot.  Actin 
was used as a loading control. 
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8hr Post Drug Addition 
24hr Post Drug Addition 
Figure 3.21 Effects of SAHA on GCVTP levels.  U251tk cells were  incubated  
with 0.1µM [3H]GCV (IC90) for either 8hr (top) or 16hr (bottom).  At the end of  
drug incubation cells were harvested and nucleotides were purified by acid  
extraction.  [3H]GCVTP metabolites were separated by HPLC and quantified by  
scintillation counting.  Columns, mean; bars, SE 
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24hr Post Drug Addition 
8hr Post Drug Addition 
Figure 3.22 GCVMP incorporation into DNA.  U251tk cells were incubated 
with either 0.1µM [3H]GCV  (IC90) for either 8hr (top) or 16hr (bottom).  At  
the end of drug incubation cells were harvested.  Nucleic acids were purified 
by acid extraction.  DNA was pelleted by centrifugation and resuspended.  
Incorporated [3H]GCVMP was measured by scintillation counting.  Columns, 
mean; bars, SE 
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Figure 3.23 Effects of SAHA on endogenous dNTP pools.  U251tk cells were  
incubated with either IC90 GCV, 10µM SAHA alone or both IC90 GCV and 10µM  
SAHA for 24h. At the end of drug incubation cells were harvested, nucleotides  
were purified by acid extraction endogenous dNTP pools were seperated and  
measured by HPLC.  Columns, mean; bars, SE 
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Figure 3.24 CtIP expression in response to SAHA. U251tk cells were incubated  
with the indicated concentration of SAHA alone (left) or SAHA and IC90 GCV  
(right) for 24hr. CtIP was assessed by western blot.  Actin was used as a loading  
control.  
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Figure 3.25 Rad51 expression in response to SAHA. U251tk cells were 
incubated with the indicated concentration of SAHA alone (A) or SAHA and IC90 
GCV (B) for 24hr. rad51 was assessed by western blot.  Actin was used as a 
loading control.  
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Figure 3.26 SAHA inhibits GCV induced Rad51 foci formation. U251tk cells 
were incubated with 1, 3, or 10µM of SAHA alone or with an IC90 GCV for the 
indicated times. Cells were assayed by confocal microscopy for Rad51 at the 
indicated time points (positive cell = >10 Rad51 foci).  Black bar indicates 
duration of drug incubation, points represent the mean of at least two wells 
from a representative experiment, error bars represent standard error.   
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Figure 3.27 SAHA inhibits HR repair. Hela-D-GFP-TK cells were incubated in the  
indicated concentration of SAHA either with or without the AdNGUS24i 
adenovirus containing the cDNA for the I-SceI enzyme.  48hr later, cells were 
collected, fixed and assessed for GFP expression by flow cytometry. Bars 
represent a mean of at least three experiments run in triplicate, error bars 
represent standard error.  
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Figure 3.28 Sensitivity of HeLa-D-GFP-TK cells to SAHA. Exponentially 
growing HeLa-D-GFPtk cells were exposed to increasing concentrations of 
SAHA for 24hr. Survival was determined by  a clonogenic cell survival assay 
and expressed as a fraction of plating efficiency for untreated cells.  Points 
represent the mean of at least three wells from a representative 
experiment, error bars represent standard error. 
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Figure 3.29 Cell cycle effects of GCV and SAHA. U251tk cells were incubated 
with IC90 GCV and/or the indicated concentrations of SAHA. At the indicated 
time points cells were collected, fixed, and cell cycle was analyzed by flow 
cytometry based on DNA content. Columns represent the cell cycle 
distribution of a representative sample at the indicated time point.   
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irs1SFTK 
Figure 3.30 Isobologram Analysis of GCV and SAHA in AA8TK or irs1SFTK 
cells Exponentially growing AA8TK (top) or irs1SFTK (bottom) cells were 
exposed to increasing concentrations of GCV and/or SAHA for 16hr.  Survival 
was determined by  a clonogenic cell survival assay and expressed as a 
fraction of plating efficiency for untreated cells.  Data from the clonogenic 
survival curves were used to generate isobolograms.  The concentration of 
ganciclovir corresponding to IC10, IC25, IC50, and IC90 surviving fractions were 
used alone or in combination with SAHA (1, 3, and 10, 30µM and 0.3, 1, 3, 
and 10µM for AA8tk and irs1SFtk, respectively).  Fractions portray a 
representative experiment plated in triplicate.  Diagonal line,  
isoeffective line of additivity. 
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Chapter IV  
Conclusion 
Suicide gene therapy is a selective approach for the treatment of cancer.   HSV-
TK/GCV suicide gene therapy is one of the most commonly used approaches due to its 
exquisite selectivity and tumor cell kill.  Despite the fact that it has been almost twenty 
five years since the first publication with HSV-TK/GCV gene therapy, the exact 
mechanism by which GCV causes cell death is yet to be elucidated.  However, it is well 
accepted that incorporation of GCVMP into DNA is a requirement for GCV to be 
cytotoxic.  The pathways between incorporation and cell death still remain unclear.  
Elucidating this mechanism may uncover novel pathways important for killing tumor 
cells as well as identify new mechanism-based drug combinations with HSV-TK/GCV 
gene therapy.  In light of this, the primary objectives of this dissertation were to 1) 
determine the cellular processes evoked in response to having GCVMP in the DNA 
template and 2) to pharmacologically exploit these processes to enhance GCV mediated 
cell killing.   
Previous studies have demonstrated that GCV has a unique mechanism of cell 
killing compared to most nucleoside analogs such as the less cytotoxic compound 
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araT(1).  Most analogs, including araT, inhibit DNA synthesis in the cell cycle after drug 
addition when being incorporated into nascent DNA resulting in cell death(1).  GCV 
causes cell death in the second cell cycle after drug addition suggesting GCVMP in the 
template strand of DNA is the cytotoxic lesion in response to GCV.   
In addition to a unique cell cycle disruption, previous reports demonstrate that 
GCV treatment results in sister chromatid exchanges (SCEs) where another HSV-TK 
substrate, acyclovir, did not.  SCEs are thought to be the result of aberrant homologous 
recombination (HR).  Using rad51 foci formation as an indicator of HR, we demonstrate 
that HR responds to GCV induced DNA damage in the second cell cycle after the 
addition of GCV when cell death occurs.  In chapter III of this dissertation, I demonstrate 
that HR promotes survival in response to GCV in mammalian cell lines.  Based on these 
observations, one may conclude that, of all HSV-TK substrates, only GCV activates the 
DNA repair pathway of HR.  However, this is not the case as araT also activated HR in 
response to araT suggesting the activation of HR alone cannot explain the differences in 
cytotoxicity between GCV and araT.  The observation that only GCV induces SCEs yet 
other analogs activate HR suggests attempting to repair GCVMP in the template results 
in unique disruption of HR repair.   
One possible step of HR repair that could be inhibited by GCVMP in template 
DNA is the resection step.  During DNA repair by HR, DNA is resected in a 5’ to 3’ 
direction around the damaged area.  This generates a 3’ overhang that invades the sister 
chromatid where it serves as a primer to resynthesize the damaged area preventing any 
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loss of genetic material.  If the damage occurs at a replication fork, such as what might 
be expected from the DNA polymerase being unable to replicate DNA across from 
GCVMP, the template strand of DNA is resected so that extension of the nascent strand 
can continue from the sister chromatid.  In the context of HR repair of GCV induced DNA 
damage, this indicates the resection machinery must remove GCVMP from the template 
DNA in order to complete repair.  Interestingly, genetic studies have demonstrated that 
compromised DNA resection during HR results in deleterious chromosomal 
abnormalities such as chromosomal breaks(2), which also occur as a result of GCV 
treatment(3).  Furthermore, previous studies have demonstrated that GCVMP remains 
in DNA for as long as 96hr after removal of GCV from cells(1).   Collectively, these 
findings support the hypothesis that GCVMP in template DNA may inhibit DNA resection 
during repair.  If this hypothesis is correct, that GCVMP is inhibiting the completion of 
HR repair, it would suggest that the unique mechanism of GCV cytotoxicity involves 
damaging DNA and then inhibiting the subsequent repair.  This observation could also 
explain why GCV is more cytotoxic than araT despite lower incorporation of GCVMP into 
DNA compared to araTMP(1).  Furthermore, in chapter II of this dissertation I 
demonstrate that GCV induces more ATM activation than araT suggesting more DNA 
double strand breaks (DSBs) are produced with GCV versus araT.  Alternatively, the 
inhibition of resection by GCVMP may result in a persistent number of DNA DSBs that 
cannot be repaired resulting in persistent activation of ATM.  Conversely, araT may 
induce more lesions than GCV that are repaired quickly allowing DNA replication to 
continue with subsequent inactivation of the DSB response.  This would support the 
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hypothesis that GCV causes cell death by inducing unrepairable DNA damage whereas 
araT causes cell death by overwhelming cells with replication stress.  Importantly, this 
suggests that selecting for drugs or drug combinations that induce DNA damage and 
inhibit the subsequent repair of this damage may be useful in future drug development.   
A second possibility of the mechanism by which GCV may cause cell death in the 
second cell cycle is through the inhibition of the restart of DNA synthesis during HR.  
After GCV causes stalling of DNA synthesis, HR is used to restart replication from the 
newly synthesized sister chromatid.  Due to the semi-conservative nature of DNA 
replication, the newly synthesized sister chromatid should not have GCVMP 
incorporated into DNA.  However, GCV treatment results in sister chromatid 
exchanges(1) suggesting the GCVMP containing DNA template may have been 
exchanged with the newly synthesized sister chromatid.  This gives rise to the possibility 
that, GCVMP containing sister chromatid is used DNA to restart DNA synthesis which 
could result in a second stalling of DNA synthesis and ultimately failed HR due to 
inability to restart DNA replication.   
The observation that HR promotes survival after GCV treatment indicates 
pharmacological inhibition of HR will enhance the cytotoxicity of GCV.  Previous studies 
have demonstrated that compounds which inhibit lysine deacetylase enzymes (KDACs) 
decrease HR required proteins(4) and block rad51 foci formation after IR in human cell 
lines(4).  Further, KDAC inhibitors have been demonstrated to decrease resection during 
HR in yeast(5).  In chapter III of this dissertation, we demonstrate that the KDAC 
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inhibitor SAHA synergistically kills HR proficient cells.  Further, we demonstrate that 
SAHA decreases the protein levels of rad51 and decreases the number of HR events in a 
cell based assay.  Strikingly, we observed synergistic tumor cell kill in HR proficient cell 
lines and only additive cell kill in a matched, HR deficient cell line.  Collectively, these 
data suggest the synergistic cell kill observed with GCV and SAHA is due to SAHA 
inhibiting the HR mediated DNA repair of GCV induced DNA damage.  Interestingly, we 
observed that SAHA treatment resulted in a decrease in protein levels of CtIP in 
combination with GCV.  CtIP is an exonuclease responsible for resecting DNA during HR.  
The decrease in CtIP after SAHA treatment indicates both GCV and SAHA may inhibit HR 
by inhibiting DNA resection.  The in vitro data provided in this dissertation warrants 
further studies to evaluate this novel combination in vivo.  Additionally, these data 
support the hypothesis that selecting for drugs or drug combinations that induce DNA 
damage and inhibit the subsequent repair of this damage will be useful in future drug 
development.   
HR is a multi-step DNA repair pathway and rationally deciding which step to 
inhibit may be difficult.  The studies in this dissertation suggest that targeting DNA 
resection during HR may be a novel mechanism for increasing tumor cell kill.  Genetic 
mutations that compromise HR results in increased susceptibility to cancer.  
Compromising DNA resection during HR results in genomic instability and chromosomal 
abnormalities(2), both of which occur in response to GCV treatment in HSV-TK 
expressing cells(3).  The advantage to using GCV in a gene therapy strategy for the 
treatment of cancer is that only the tumor cells are capable of activating GCV to the 
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cytotoxic form.  Therefore, normal tissues are spared not only from cell death but also 
from deleterious genomic insults that may result in secondary cancers.  This suggests 
that, due to the potential toxicities and risk for secondary cancers, the best approach for 
exploiting this combination would be transient pharmacological inhibition of DNA repair 
with localized DNA damage, both of which are provided by HSV-TK/GCV gene therapy in 
combination with SAHA.  Additionally, this has broader implications for other targeted 
approaches that damage DNA such as IR.   
In conclusion, the results presented in this dissertation increase the knowledge 
of the mechanism of GCV mediated killing of tumor cells and identifies SAHA as a novel 
compound to enhance HSV-TK/GCV gene therapy.  Additionally, the results identify DNA 
resection during HR as a potential target for future drug development.  Finally, these 
studies demonstrate that investigations into pharmacological mechanisms of existing 
drugs can provide an opportunity to discover novel drug targets that may lead to new 
drugs with greater antitumor efficacy.  
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Due to semi-conservative DNA replication, GCVMP  
is incorporated into one strand  of DNA in each  
daughter cell 
SCEs , however, result  in GCVMP 
containing DNA to be in the newly 
synthesized  sister chromatid  
GCV is removed from cells after the first cell 
cycle and therefore should  not be in newly 
synthesized DNA in  the second cell cycle    
If HR attempts to restart DNA 
replication stalling in response to  GCV 
by using the sister chromatid as a 
template and the replication  
machinery encounters another  
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cycle 
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Figure 4.1 GCV potentially inhibits DNA replication restart during 
HR.  Schematic of a possible mechanism of GCV mediated cell death.  
If HR occurs in response to GCVMP in the DNA template downstream 
of a SCE, HR may encounter another GCVMP in the DNA template of 
the sister chromatid resulting in failed HR and cell death. 
164
Reference List 
 
 1.  Rubsam, L. Z., Davidson, B. L., and Shewach, D. S. (1998) Cancer Res 58, 
3873-3882 
 2.  Eid, W., Steger, M., El Shemerly, M., Ferretti, L. P., Pena-Diaz, J., 
Konig, C., Valtorta, E., Sartori, A. A., and Ferrari, S. (2010) EMBO Rep. 11, 
962-968 
 3.  Tomicic, M. T., Bey, E., Wutzler, P., Thust, R., and Kaina, B. (2002) 
Mutat.Res. 505, 1-11 
 4.  Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., 
and Buggy, J. J. (2007) Proceedings of the National Academy of Sciences 
104, 19482-19487 
 5.  Robert, T., Vanoli, F., Chiolo, I., Shubassi, G., Bernstein, K. A., 
Rothstein, R., Botrugno, O. A., Parazzoli, D., Oldani, A., Minucci, S., and 
Foiani, M. (2011) Nature 471, 74-79 
 
 
165
